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ABSTRACT 
 
 
Alpha-1-Antitrypsin Deficiency (AATD) is a risk factor for the development of early-
onset emphysema and airflow obstruction. The current work defines exacerbations, lung 
function and health status in these patients including sibling pairs.  
Exacerbations occur commonly in AATD and are associated with worse health status. 
Exacerbations were associated with a decline in the gas transfer of the lung over time, 
but show no relationship to changes in forced expiratory volume in one second (FEV1). 
However, despite lung function decline, patients do not show a progressive loss in 
health status.  
Index patients have worse lung function and health status and more emphysema than 
non-index siblings. These differences are not solely explained by smoking or 
ascertainment. Although FEV1 values differ between sibling pairs, gas transfer does 
show significant correlation. Thus disease phenotype may also be influenced by other 
genetic modifiers.  
These results provide a firm basis upon which to design, power and implement trials of 
interventions that may reduce exacerbations and improve health status in patients. 
Furthermore sibling pairs, particularly those with discordant disease or concordant 
parenchymal disease, are an ideal group to further investigate the contribution of other 
genes in the development of COPD or its phenotype in AATD patients.  
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 1
1 INTRODUCTION 
1.1 Chronic Obstructive Pulmonary Disease 
Chronic Obstructive Pulmonary Disease (COPD) is a disease of the lungs and is a major 
cause of morbidity worldwide. Prevalence studies have shown that between 4 and 10% 
of the population of Europe and North America have COPD (Halbert et al, 2003). 
COPD is also a major cause of mortality and led to 25, 765 deaths in 2003 in the United 
Kingdom alone (Office for National Statistics, 2004). Furthermore, the impact of this 
condition is increasing due to the aging population and the increased use of tobacco. 
Over the next two decades COPD is predicted to move from the twelfth to the fifth 
greatest worldwide medical burden (Lopez et al, 1998).  
 
1.1.1 Definition of COPD 
The terminology for this condition has varied in the past: chronic airflow limitation, 
chronic obstructive lung disease, chronic bronchitis and emphysema. Chronic 
Obstructive Pulmonary Disease is now the preferred description although chronic 
bronchitis and emphysema are still applicable to aspects of this condition. COPD is 
defined by “airflow limitation that is not fully reversible”. The current consensus 
definition also states that the airflow limitation in this disease is “usually both 
progressive and associated with an abnormal inflammatory response of the lungs to 
noxious particles or gases” (Pauwels et al, 2001).  
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1.1.2 Diagnosis and Assessment of COPD 
1.1.2.1 Symptoms 
Patients with COPD present to health services with a variety of symptoms including 
breathlessness, cough, sputum production and wheeze. In addition, the systemic effects 
of the disease may lead to fatigue, reduced exercise tolerance, weight loss and 
depression. These symptoms may vary between individuals and may change within an 
individual over time. Symptoms of chronic cough and sputum production may precede 
the development of airflow obstruction although not all individuals with these 
symptoms will develop COPD. 
1.1.2.2 Clinical Examination 
The physical signs that may be detected in patients with COPD are not specific to the 
condition and are often not sensitive for detecting or excluding the disease. Airflow 
obstruction may lead to prolonged forced expiration time and pursed lip breathing may 
be observed in patients in an attempt to reduce airway collapse in expiration. In 
advanced disease there may be evidence of cyanosis, weight loss and the use of 
accessory muscles of respiration. Overinflation may lead to increased thoracic kyphosis 
and a barrel-shaped chest, together with reduced distance between the cricoid cartilage 
and the suprasternal notch. Overinflation may also be demonstrated by reduced cardiac 
dullness to percussion and soft heart sounds. Auscultation may reveal reduced breath 
sounds with prolonged expiratory phase and wheeze may be present. Crackles are often 
detected particularly at the lung bases. 
Furthermore, consequences of severe disease may be detected on examination including 
signs of pulmonary hypertension, hypercapnia, cachexia and depression. 
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1.1.2.3 Lung Function 
Airflow limitation is detected by objective measurement using spirometry and this 
limitation largely remains when bronchodilator agents are given. The measurements 
made during spirometry are the forced expiratory volume in 1 second (FEV1), the forced 
vital capacity (FVC) and the ratio of these 2 measures (FEV1/FVC). Airflow obstruction 
is defined as an FEV1/FVC ratio of less than 70% with or without a reduction in FEV1 
(Pauwels et al, 2001; Fabbri et al, 2003). COPD is not the sole cause of airflow 
obstruction and other conditions, such as asthma, bronchiectasis and bronchial 
carcinoma, need to be excluded. In early disease, conventional spirometry may be 
normal but measures of small airway function, such as flow rates at low lung volumes, 
may be abnormal. However, in routine clinical practice, conventional spirometry in 
usually abnormal by the time the patient presents to health care services with symptoms. 
Additional measurements of lung function may also show abnormalities in COPD 
patients. Patients may have an increase in the Total Lung Capacity (TLC), which is the 
volume of gas in the lungs and airways at full inspiration, due to overinflation. There 
may also be trapping of air within the lungs as demonstrated by an increase in Residual 
Volume (RV), which is the volume of gas remaining in the lungs at full expiration. 
Static lung volumes may be measured using steady state helium dilution (Meneely et al, 
1949) or by whole body plethysmography (Dubois et al, 1956). The helium dilution 
method assumes that the lungs are well ventilated which may not be the case in patients 
with severe obstructive defects or bullous emphysema. Thus in some cases helium 
dilution may underestimate TLC. 
The ability of the lungs to transfer oxygen from air into the circulation may be reduced 
in COPD patients. This can be quantified by the measurement of the rate of gas transfer 
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across the alveolar membrane (TLCO) and can be adjusted for alveolar volume to 
acquire a value of gas transfer per unit of lung (KCO) (Blakemore et al, 1957). 
Furthermore, measurement of arterial blood gases may indicate hypoxaemia. 
Disease staging of COPD patients is currently based on the severity of airflow limitation 
as detected by FEV1. However this staging has limitations and it does not account for 
differences in symptoms, functional ability or pathological changes within individuals. 
Thus patients within the same disease stage may vary greatly and comprehensive 
assessment of COPD patients should include measures of these other parameters. 
1.1.2.4 Radiology 
Plain chest radiography does not show any specific abnormalities in COPD patients and 
indeed may be normal. Abnormalities that may be seen include low and flattened 
diaphragms and an increase in the retrosternal airspace due to hyperinflation. There may 
also be a reduction in the size and number of pulmonary vessels and focal translucency 
may be seen in areas of bullous formation. Areas of increased lung markings may also 
be seen in regions of atelectatic or scarred lung. 
Computed tomography (CT) is a more accurate method for radiological assessment of 
the lungs and is more sensitive than plain radiography in detecting emphysema (Sanders 
et al, 1988). Macroscopic emphysema is visualised on CT scans as areas of low 
attenuation with thinning of the corresponding vascular tree and has been shown to 
correlate with pathology scores (Kuwano et al, 1990). Furthermore, methods of 
objective quantification of emphysema on CT scans have been developed (Gevenois et 
al, 1995; Thurlbeck et al, 1994). Scans may be analysed to assess the number of pixels 
with a density lower than a predetermined threshold to obtain a measurement which 
may be used to compare patients or monitor groups of patients over time. However, 
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many factors may influence the results including scanner performance, the age of the 
patient and the ventilatory volume at the time of acquisition of the scan. Thus the 
usefulness of these measurements outside clinical trials may be limited. Validation 
studies of these methods of quantification of emphysema on CT scans continue. 
1.1.2.5 Inflammatory Response 
The “abnormal inflammatory response” that occurs in COPD which is described in the 
consensus definition has been well demonstrated in the research setting. However this is 
more difficult to measure in regular clinical practice and so individuals are often 
diagnosed with COPD based upon their history, clinical findings and pulmonary 
function tests.  
 
1.1.3 Pathology of COPD 
The underlying cause of the airflow limitation in COPD is complex. Pathological 
changes within large and small airways as well as destruction of the alveolar airspaces 
may all contribute to airflow limitation. The relative contribution of pathological 
changes within different parts of the lungs may vary between individuals with COPD 
and this may contribute to different phenotypic expression of disease.  
The complex pathological changes in COPD can be simplified by considering the three 
affected compartments separately, namely the bronchi, peripheral airways and alveolar 
airspaces. 
1.1.3.1 Bronchial Pathology 
Healthy bronchi contain submucosal glands and goblet cells which decrease in number 
and size down to the peripheral bronchi and are absent in the bronchioles. Some patients 
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with COPD have chronic bronchitis which is defined clinically by an increase in sputum 
production. The bronchi of these patients show an increase in the number and size of 
submucosal glands particularly in the larger bronchi.  The number and distribution of 
goblet cells also change in smokers but these changes are not consistent between 
individuals. Inflammation and scarring is also seen in bronchi of COPD patients and 
this contributes to airway thickening and luminal narrowing. 
1.1.3.2 Small Airways Disease 
Many pathological changes may be seen in small airways disease ranging from 
inflammatory infiltration to airway wall thickening and fibrosis. Mucus production and 
inflammatory cell infiltrate may lead to occlusion of the lumen which may further 
contribute to airflow obstruction. 
1.1.3.3 Alveolar Pathology 
Normal acinar structure consists of respiratory bronchioles, alveolar ducts, terminal 
alveolar sacs and alveoli. The alveolar walls are thin and contain types I and II 
pneumocytes, basement membranes, interstitium and endothelial cells. It is here that the 
gas transfer of oxygen and carbon dioxide occurs. 
Emphysema may be a component of COPD and is defined structurally as “abnormal, 
permanent enlargement of the airspaces, distal to the terminal bronchioles, accompanied 
by destruction of their walls and without obvious fibrosis” (National Heart Lung and 
Blood Institute, 1985). Emphysema may be subdivided into 3 types based on anatomical 
distribution within the secondary lobule: centrilobular emphysema is clustered around 
the terminal bronchiole; panlobular emphysema is distributed throughout the acinar 
unit; and paraseptal emphysema occurs along the edge of the acinar unit. Centrilobular 
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and panlobular emphysema are more common and each of these subtypes is often 
associated with a characteristic distribution within the lungs. Centrilobular emphysema 
often affects the upper zones of lobes whilst panlobular emphysema is seen more in the 
lung bases. Alveolar attachments to small airways play an important role in maintaining 
airway patency and loss of these attachments in emphysematous lung allows 
surrounding airways to collapse, particularly in expiration, contributing to airway 
occlusion. 
 
1.1.4 Pathogenesis of COPD 
The risk of developing COPD is affected by a combination of genetic and 
environmental factors. Cigarette smoking is the most important environmental risk in 
this condition, particularly in the Western world. Other environmental risks include 
occupational mineral dust exposure (Oxman et al, 1993), biological dust exposure 
(Matheson et al, 2005), indoor pollution from fuel and outdoor air pollution. 
In addition, it is likely that several genetic susceptibility factors influence the effect of 
smoke and other environmental agents on an individual. This gene/environment 
interaction may determine not only the development of COPD but also the rate of 
progression of the disease.  
1.1.4.1 Smoking 
Smoking may lead to symptoms of cough, sputum and wheeze and these symptoms may 
improve after smoking cessation (Tashkin et al, 1984). Moreover, there is also a clear 
dose-dependent relationship between the amount of cigarettes smoked and the risk of 
irreversible airflow obstruction (Burrows et al, 1977). However this relationship is not 
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absolute and only a minority of smokers develop COPD (Fletcher et al, 1977). In 
addition, a minority of patients with COPD have never smoked although they may have 
been exposed to other environmental agents such as coal.  
Cigarette smoke contains many harmful compounds, including oxygen free radicals, 
polycyclic aromatic hydrocarbons, nitrosamines, nitrogen oxides and other oxidants. 
These compounds not only have direct cytotoxic effects but also lead to an 
inflammatory response within the lungs. 
1.1.4.2 Inflammation 
Sputum induction, bronchial lavage and bronchial biopsy studies have shown an 
increase in the number of T lymphocytes, macrophages, eosinophils and neutrophils in 
COPD patients. However the key causative inflammatory cell in the pathogenesis of 
COPD is probably the neutrophil. Neutrophils migrate to sites in response to 
upregulation of cell-surface adhesion molecules (such as e-selectin and ICAM-1) on 
endothelial and epithelial cells. The principal mediators of this inflammation are 
Leukotriene B4 (LTB4), Interleukin 8 (IL-8) and Tumour Necrosis Factor-α (TNF-α). 
1.1.4.3 Protease-Antiprotease Imbalance 
One theory on the development of emphysema in smokers is that an imbalance occurs 
between proteases released from neutrophils and antiproteases in the interstitium. 
Neutrophils are activated and migrate through endothelial cells and the interstitium into 
airspaces in response to cigarette smoke and chemoattractants. Proteases, including 
elastase, proteinase 3, cathepsin G and matrix metalloproteinases, are released from 
neutrophils during migration and these bind to elastin causing tissue destruction. 
Antiproteases, such as alpha-1-antitrypsin (AAT) and secretory leukoproteinase 
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inhibitor (SLPI), are found in the interstitium and may inactivate released elastase and 
limit the area of damage. However an insufficient quantity of antiprotease or an excess 
amount of protease will lead to an imbalance in this system and significant tissue 
destruction will ensue.  
This hypothesis is supported by the observation that intrapulmonary instillation of 
elastolytic enzymes produces emphysema in animal models (Gross et al, 1965; Senior et 
al, 1977). Moreover, humans with reduced levels of antiprotease, such as that seen in 
alpha-1-antitrypsin deficiency, have an increased risk of emphysema particularly if their 
lungs are exposed to pollutants such as cigarette smoke. 
 
1.1.5 Genetic Risk Factors 
Airflow obstruction is not seen in every individual who smokes and there appears to be 
a sub-population that is susceptible to accelerated decline in lung function. The 
hypothesis of genetic susceptibility factors has been supported by the observation that 
early-onset COPD may be seen in more than one subject within a family. Severe early-
onset COPD subjects may have a high carrier rate for COPD susceptibility genes as 
may be seen in early onset cases of other complex diseases such as breast cancer. One 
study of early onset COPD is the Boston Early-Onset COPD Study which investigated 
44 severe COPD patients and 204 of their first degree relatives with comparison to 83 
control subjects (Silverman et al, 1998). The relatives of these early-onset COPD 
probands showed significantly lower FEV1 values, despite similar age and pack year 
smoking history, with a relative risk of three for reduced FEV1 and also for chronic 
bronchitis. However, this increased risk seems to be limited to current or ex-smokers, as 
there was no increased risk for reduced FEV1 seen in relatives who were lifelong non-
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smokers. This suggests that these genetic risk factors for COPD are expressed in 
response to cigarette smoking. Interestingly, this risk may be influenced by gender as 
female smoking first-degree relatives in one study were significantly more likely to 
demonstrate profound reductions in FEV1 than male smoking first-degree relatives 
(Silverman et al, 2000). 
Identification of genes that may influence the risk of developing COPD has proved 
difficult. Association studies have shown inconsistent results which might be explained 
by genetic heterogeneity of the study populations. Conversely, case-control association 
studies may find associations purely due to stratification of the populations. Linkage 
studies which identify areas of the genome which are likely to contain susceptibility 
genes may prove more helpful. One such linkage study has demonstrated evidence for 
an early-onset COPD-susceptibility locus on chromosomes 2 and 12 and further 
suggestive evidence for linkage of spirometry-related phenotypes to several other 
genomic regions (Silverman et al, 2002b; Silverman et al, 2002a). Palmer et al again 
found significant linkage to airflow obstruction susceptibility loci on chromosomes 2q 
as well as 8p (Palmer et al, 2003). Linkage of spirometric measurements to a locus on 
chromosome 2 has also been replicated in the general population (Malhotra et al, 2003). 
Taken together these studies suggest that the genetic risk factors for COPD are likely to 
be multiple and many remain ill-defined. However, one important genetic risk factor for 
the development of COPD that has long been well established is severe alpha-1-
antitrypsin deficiency. 
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1.2 Alpha-1-Antitrypsin Deficiency 
Alpha-1-antitrypsin deficiency (AATD) is a risk factor for the development of 
respiratory symptoms, early-onset emphysema and airflow obstruction in adult life and 
was first described by Eriksson and Laurell in 1963 (Eriksson, 1963; Laurell et al, 
1963). AATD may also lead to the development of acute or chronic liver disease in 
childhood or adulthood and has been linked to other systemic diseases such as 
panniculitis and fibromyalgia. 
 
1.2.1 Alpha-1-Antitrypsin 
Alpha-1-Antitrypsin (AAT) is a 394 amino acid, 52 kDa protein which is encoded on 
chromosome 14q31-32.1 (Billingsley et al, 1993) and is a member of the serpin (serine 
proteinase inhibitor) family. The main biological role for AAT is to inactivate 
neutrophil elastase (NE) (Beatty et al, 1980) through irreversible binding via the 
reactive site. AAT is mainly synthesised in hepatocytes (Koj et al, 1978), although 
mononuclear phagocytes, intestinal and bronchial epithelial cells may synthesise small 
amounts (Cichy et al, 1997; Mornex et al, 1986; Perlmutter et al, 1989). AAT is an 
acute phase protein and the levels in the serum and airways may increase in an 
individual during times of systemic inflammation or stress. However the average serum 
concentrations are determined within an individual by the genetic alleles carried. Some 
genes lead to reduced levels of AAT and these subjects are said to have alpha-1-
antitrypsin deficiency. The serum concentration of AAT in severely deficient patients is 
usually less than 11 μM although the actual concentration may change slightly over 
time as part of an acute phase response. 
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1.2.2 Genetics of AATD 
The genetic locus for alpha-1-antitrypsin is highly polymorphic and over 100 alleles and 
their consequent protein variants have been described. The most common variants in 
white populations are the M alleles which are associated with normal serum AAT 
levels. The S allele is associated with slightly reduced AAT levels and the Z allele, 
which has a single base pair substitution (Jeppsson, 1976), leads to markedly reduced 
serum AAT. Null alleles are carried by a small percentage of individuals and lead to no 
detectable protein due to deletion of coding regions or defective gene translation. 
Testing for AAT is frequently performed using serum isoelectric focusing which detects 
bands of proteins separated by their differing charge. A protein strip which shows only a 
Z band may represent protein translated from 2 Z alleles or one Z and one null allele, 
and so, as isoelectric focusing cannot distinguish between these two possibilities, these 
individuals are referred to as phenotype PiZ. If required, actual genotyping can be 
elucidated using allele specific hybridisation.  
The altered protein structure of Z AAT protein, caused by the point mutation at the base 
of the reactive loop of the molecule, leads to polymerisation of the Z AAT.  These 
polymers accumulate in the endoplasmic reticulum of hepatocytes. Furthermore this 
polymerisation impairs secretion of AAT from the liver resulting in reduced serum 
levels of around 10% of the amount produced from a normal M allele.  
AATD is inherited in an autosomal co-dominant manner and offspring of 2 
heterozygote parents have a 1 in 4 chance of being homozygotes and consequently 
having severe deficiency.  
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1.2.3 Incidence of AATD 
The incidence of AATD varies between studied populations and the highest frequency 
of the Z gene is seen in Scandinavia (Hutchison, 1998) which may represent a common 
mutational origin for the vast majority of Z alleles. Low Z allele frequencies are seen in 
populations of Asian and African descent.  Many studies on incidence are limited by 
ascertainment bias as asymptomatic individuals may not present to health services and 
therefore remain undetected. Population screening is not widely performed although one 
large comprehensive study has been performed in Sweden. In this study 200,000 babies 
born over a 2 year period were screened and 122 children were identified as PiZ 
phenotype, giving a prevalence of 1 in 1640 (Sveger, 1976).  
Studies on the prevalence of PiZ individuals amongst patients with a diagnosis of 
COPD show variable results between 1 to 10% (Fagerhol et al, 1969; Lieberman, 1969; 
Lieberman et al, 1986). These figures are affected not only by the incidence within the 
population but also by variations in screening practice. 
 
1.2.4 Identification of Patients 
Patients may be diagnosed with alpha-1-antitrypsin deficiency after presentation with 
symptoms or through family screening of an index case. The proportion of patients 
identified by screening is influenced by local and national practice and thus studies of 
groups of patients may show some differences. In the UK registry of AATD, 76% of 
PiZ patients have been identified through investigation of respiratory symptoms or 
disease and 19% through family screening. Similar proportions are reported in the 
National Heart Lung and Blood Institute (NHLBI) registry (McElvaney et al, 1997). A 
small number of subjects are identified through abnormal radiological, pulmonary or 
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blood tests or through the development of liver disease. In the UK registry, only 3% of 
patients have been identified as a result of liver disease, although it is possible that 
greater numbers of such patients are identified and treated elsewhere. 
There can often be a delay in the diagnosis of AATD and one study has shown a 
duration of seven years between mean age of onset of symptoms and the mean age of 
subsequent diagnosis (Stoller et al, 1994). Patients often present in the third or fourth 
decade with symptoms of breathlessness and other common symptoms include cough, 
phlegm, wheeze (with and without infections) and fatigue (McElvaney et al, 1997; Eden 
et al, 2003). 
A few studies have followed deficient individuals after detection through neonatal 
screening and these are more representative of the population of individuals with this 
condition. However, the largest cohort has only been studied for 25 years so far 
(Piitulainen et al, 2002), providing little data on the natural history of the condition 
through adult life. 
 
1.2.5 Lung Disease 
1.2.5.1 Molecular Basis of Lung Disease in AATD 
Alpha-1-antitrypsin diffuses from the serum through the pulmonary endothelium into 
the lung interstitium where it protects against tissue destruction by proteinases. 
Neutrophils migrate from the circulation into the airways and release elastase from their 
azurophil granules. The concentration of elastase is around 5mmol which is three times 
the concentration of normal alpha-1-antitrypsin (Liou et al, 1995). Thus, even with 
normal AAT levels there has to be a region of uninhibited enzyme activity close to the 
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site of enzyme release. In conditions of reduced AAT levels, such as that seen in 
deficient patients, both the radius and duration of catalytic activity is increased which 
leads to a larger area of connective tissue destruction by migrating neutrophils. 
Furthermore uninhibited elastase may stimulate macrophages to produce LTB4 
(Hubbard et al, 1991). This chemoattractant leads to increased migration of neutrophils 
and thus amplifies the inflammatory process. This mechanism is supported by the 
observation that AAT deficient individuals have significantly greater neutrophil counts 
in bronchoalveolar lavage samples (Morrison et al, 1987) and in tissue samples. 
Moreover sputum from patients with AATD has higher concentrations of LTB4 and IL8 
and greater chemotactic activity than controls (Woolhouse et al, 2002) which leads to 
greater neutrophil traffic. 
Not only is there less AAT in AATD but the Z protein may also be a less effective 
inhibitor of neutrophil elastase than the normal M protein (Lomas et al, 1993; Ogushi et 
al, 1987). Furthermore this “functional deficiency” may potentially be worsened by 
reduction in AAT activity through oxidation in patients who smoke (Gadek et al, 1979; 
Janoff et al, 1979). 
More recently it has been suggested that polymerisation of Z protein within the lungs of 
deficient patients may also contribute to the pathogenesis of this condition (Elliott et al, 
1998). Loop-sheet polymers of AAT are inactive and consequently their genesis within 
the lung may further reduce the level of functional protease inhibitor that is available to 
protect the lungs from damage. Furthermore polymeric alpha-1-antitrypsin has 
chemotactic activity for neutrophils in vitro (Parmar et al, 2002) and may amplify the 
inflammatory response and subsequent damage. 
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Thus the mechanisms behind the development of COPD in alpha-1-antitrysin deficiency 
appear to be complex and the relative contribution of smoking, infections, cytokines and 
AAT polymerisation remains undefined. 
1.2.5.2 Emphysema 
The close association of AATD and the development of emphysema was first described 
in 1963 (Eriksson, 1963). The disease in these patients is usually of an earlier onset 
compared to patients with usual Chronic Obstructive Pulmonary Disease (COPD) and 
often appears to be out of proportion to their smoking history. The typical pattern shows 
panlobular emphysema with lower zone predominance although the emphysema may 
affect all zones. Plain chest x-rays may show evidence of hyperinflation with reduced 
lung markings and bulla formation may also be associated with emphysematous lung 
(Guest et al, 1992). Lung function tests on symptomatic patients often show evidence of 
increased lung volumes and air trapping as well as impaired gas transfer. However, this 
picture is not universal and some patients with severe airways obstruction and 
prominent emphysema on CT scan may maintain normal gas transfer (Wilson et al, 
2000).  
Furthermore the pattern and distribution of emphysema may influence the lung function 
impairment in these patients. Parr et al have shown that basal emphysema is associated 
with greater impairment of FEV1 but less impairment of gas exchange and alveolar-
arterial oxygen gradient than the apical emphysema in this disease (Parr et al, 2004). 
1.2.5.3 Airways Disease and Bronchodilator Reversibility 
Airflow obstruction, as demonstrated by a reduced FEV1 and reduced FEV1/FVC ratio, 
may be seen in deficient subjects. The amount of airflow limitation measured may fall 
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anywhere in the range between none to severe obstruction and it is often out of 
proportion to the smoking history of the patient. 
Airflow limitation in these patients is not always fixed and the symptoms and signs in 
AATD can be similar to features of asthma. Individuals can often be given a diagnosis 
of asthma in childhood or early adulthood and 15% of patients in a Swedish cohort 
identified by neonatal screening had been diagnosed as having asthma by the age of 22 
(Piitulainen et al, 2002). In the same cohort, 29% of the patient group reported recurrent 
wheezing. In the larger NHLBI registry, 21% of the total group and 12.5% of those with 
normal FEV1 had asthma as defined by reversible airflow obstruction, recurrent 
wheezing, and a reported diagnosis of asthma or allergy with or without elevated IgE 
levels (Eden et al, 2003). Studies on airway hyperresponsiveness in these patients are 
limited and group together patients of different phenotypes but they suggest that airway 
hyperresponsiveness is not more prevalent in these patients compared to control 
subjects (Malerba et al, 2003).  
There is a wide variation in bronchodilator response in these patients. In the NHLBI 
registry, 28% of patients during the first visit showed reversibility of ≥12% and >200ml 
in FEV1 and this was seen in 49% over all visits in the study (Eden et al, 2003). In these 
patients, the median increase in FEV1 was 330ml with a range of 202ml to 1,492ml, 
which explains why many patients who present at a young age are given an initial 
diagnosis of asthma. Indeed, bronchodilator responses are also seen in patients without 
a reduced FEV1 below 80% predicted and it may be that this is more common in the 
early stages of the disease. 
Although airflow obstruction and parenchymal destruction can often be seen together in 
the same patient, this is not always the case. Some patients have marked emphysema 
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with very little airways disease and the reasons for this relative preservation of airway 
function are unclear. By contrast, some patients have severe airflow obstruction with 
little parenchymal disease and show preserved gas transfer. These patients with 
discordant lung function measurements have been poorly studied and it is not known 
whether they represent a discrete phenotypic expression of this disease or have simply 
been assessed at an earlier stage of the disease process.  
1.2.5.4 Chronic Bronchitis 
Chronic bronchitis is defined clinically by the presence of cough productive of sputum 
for at least 3 months in 2 successive years if other causes of chronic cough have been 
excluded (Medical Research Council, 1965). Patient registries of alpha-1-antitrypsin 
deficient subjects show that as many as 43% of patients have chronic sputum 
expectoration, as defined by Medical Research Council (MRC) criteria, even in non-
smokers. The patients with chronic bronchitis tend to have more severe airflow 
obstruction and more extensive emphysema than those without despite similarities in 
age and smoking history (Dowson et al, 2002). 
1.2.5.5 Bronchiectasis 
Bronchiectasis is a condition of the lungs characterised by persistent abnormal dilatation 
of the bronchi. The presence of bronchiectasis in patients with AATD is well recognised 
and in series using CT scanning for detection, the incidence varies from 41% to 43% 
(Guest et al, 1992; King et al, 1996; Shin et al, 1993). However, in the largest study the 
incidence of bronchiectasis was 26% (Dowson et al, 2002) which is similar to that seen 
in usual COPD (O'Brien et al, 2000), suggesting that the incidence is not increased. In 
support of this, Cuvelier et al compared a group of patients with bronchiectasis, mainly 
 19
diagnosed by CT scan, and a group of control subjects and found similar AAT 
phenotypes and gene frequencies in the 2 groups (Cuvelier et al, 2000). A greater 
frequency of PiZ alleles was seen in those patients with bronchiectasis who also had 
emphysema but the number of patients with the PiZ phenotype was too small to provide 
firm conclusions. Although the bronchiectasis seen may be severe and associated with 
chronic sputum production, sputum expectoration itself is not a sensitive nor specific 
feature for detecting the presence of bronchiectasis and CT scanning remains the most 
reliable tool (Dowson et al, 2002). 
 
1.2.6 Factors Influencing Expression and Progression of Disease 
The degree of lung function impairment can vary greatly amongst patients with the 
same phenotype for alpha-1-antitrypsin (Tobin et al, 1983). Furthermore, case reports 
have shown that even siblings with the same phenotype show different disease 
expression (Apprill et al, 1990; Stableforth, 1978). Some environmental factors have 
been shown to affect the development and progression of disease in these patients but it 
is likely that other host factors, including other genetic modifiers, are also important. 
1.2.6.1 Smoking 
The most important risk factor for the development of emphysema and airflow 
obstruction in AATD is active smoking. Piitulainen et al have demonstrated an 
accelerated decline in FEV1 over twelve months in current smokers (70ml/year, CI 58-
82) compared to ex-smokers (41ml/year, CI 36-48) and never-smokers (47ml/year, CI 
41-53) (Piitulainen et al, 1999). Even higher rates of decline in smokers were seen in 
other studies (Janus et al, 1985; Seersholm et al, 1995). Furthermore, there appears to be 
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a dose-response relationship between the cigarette consumption and change in FEV1 
over time. Active smoking can affect lung function as early as the age of 18, with a 
significantly lower FEV1 and FEV1/VC  in those who are smoking compared to non-
smokers (Piitulainen et al, 1998a). However, active smoking does not explain all of the 
variability and patients who have never smoked still show variation in their clinical 
course (Black et al, 1978). 
Passive smoking with an exposure of greater than 10 years has been associated with 
chronic bronchitis in non-smoking individuals (Piitulainen et al, 1998b) but there has 
been no evidence to support an association between passive smoking in adulthood and 
lung function decline. However, parental smoking has been associated with some 
changes in lung function in adolescents with this condition (Piitulainen et al, 1998a) and 
it may be that passive smoking in childhood reduces the potential maximum lung 
capacity in early adulthood. 
1.2.6.2 Exacerbations 
Lower respiratory tract infections may also affect the clinical course of the disease 
(Silverman et al, 1989) and prior infections are associated with symptoms of cough and 
wheeze (Mayer et al, 2000). The effect of exacerbations may be more apparent in 
patients with mild to moderate disease and an increasing number of exacerbations has 
been shown to correlate with the decline in gas transfer (Dowson et al, 2001a). It is 
therefore likely that interventions that reduce the frequency of exacerbations may also 
reduce this decline. Indeed augmentation therapy, which may moderate lung function 
decline in some patients (Group, 1998), may also be associated with a reduction in the 
frequency and severity of exacerbations (Lieberman, 2000). It has been shown that 
infusions of AAT reduce airway leukotriene B4 concentrations (Stockley et al, 2002) 
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and this neutrophil chemotactic factor is thought to be central to the exacerbation 
episodes. Although this provides a mechanism for this association, further prospective 
clinical trials are still required to support this assumption and to explore whether all or 
only a subset of patients would benefit from this therapy. 
1.2.6.3 Environmental Factors 
Domiciliary kerosene heater usage and an agricultural occupation for a duration of at 
least 10 years have been shown to be associated with increased symptoms and 
decreased lung function in non-smoking PiZ patients in the Swedish registry 
(Piitulainen et al, 1998b). Self reported occupational exposure to gas, fumes or dust was 
found to be an independent risk factor for lung function impairment in older patients 
who had never smoked (Piitulainen et al, 1997). Mineral dust exposure, as detected by 
self-reported questionnaires, has also been shown to be independently associated with 
chronic cough and with airflow limitation after adjusting for age and smoking in a 
group of American patients with more severe disease (Mayer et al, 2000). Nevertheless, 
it is still not clear if this is due to high total inhalational exposure to many agents in 
these patients or due to a specific effect of mineral dust. Taken together, these studies 
suggest that environmental exposures may be associated with the development of 
respiratory symptoms in these patients and may also be a contributory factor to lung 
function decline. Further studies are needed to isolate the effects of individual agents 
and also to identify groups of individuals that may be more susceptible to these effects. 
1.2.6.4 Bronchodilator Reversibility 
Bronchodilator reversibility has been shown to be associated with more rapid FEV1 
decline and is an independent predictor of decline after accounting for age, gender and 
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smoking status (Eden et al, 2003; The Alpha-1-Antitrypsin Deficiency Registry Study 
Group, 1998; Dowson et al, 2001a) . Other features of asthma, such as attacks of 
wheeze and raised IgE, have not been associated with greater lung function decline in 
these studies. 
1.2.6.5 Age and Gender 
Advancing age, male gender and previous symptoms of wheezing were found to be 
independent predictors for lung function impairment in 225 Pi Z patients who had never 
smoked (Piitulainen et al, 1997) but the relationship between age and the rate of decline 
is less well understood due to other confounding factors. Eden et al found that those 
patients aged between 30 and 44 years had the most rapid decline and age remained an 
independent predictor of decline after adjustment for other confounders (Eden et al, 
2003). It is unclear whether this reflects the natural history of the disease or represents a 
cohort effect. 
1.2.6.6 Base Lung Function 
In a study on PiZ patients from the UK registry, there was a correlation between the 
initial FEV1 and its subsequent decline with the more severely affected patients showing 
the least change (Dowson et al, 2001a). Although this accelerated decline in less 
severely affected patients may illustrate a change in the disease course over time, it may 
be that survivorship bias “selects” some severe patients who are declining more slowly. 
1.2.6.7 Genetic Modifiers 
There has been little evidence to support genetic modifiers in families with more than 
one homozygote member although studies of heterozygote relatives do suggest familial 
aggregation. The “St Louis AAT Study” has investigated a series of 52 AAT deficient 
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subjects and 118 of their relatives using pulmonary function and a respiratory 
epidemiology questionnaire (Silverman et al, 1989). The investigators found that 
variability in pulmonary function was partially related to age and pack years of 
smoking. However the study also showed that Pi MZ relatives of PiZ patients with 
airflow obstruction showed lower FEV1 values than Pi MZ relatives of unaffected PiZ 
subjects (Silverman et al, 1990b). Furthermore parents of diseased PiZ individuals were 
more likely to report a history of emphysema than parents of unaffected PiZ individuals 
in the same study, which is consistent with COPD aggregation in families. Lung 
function measurements were only obtained in a subset of these families but the figures 
acquired showed a suggestive trend to worse lung function in parents of PiZ individuals 
with airways disease compared to those of individuals with preserved function. Taken 
together, these studies suggest that familial factors other than Pi type and smoking 
behaviour may influence the development of COPD in relatives of homozygotes. If 
other factors do play a role in this regard, they are also likely to modify the development 
of lung disease in PiZ individuals. 
In a separate study, segregation analysis of the residual phenotypes in 44 nuclear 
families was performed (Silverman et al, 1990a). Statistical evidence was found for an 
additional major gene, other than the Pi locus, influencing FEV1 in the study population. 
The evidence of this gene diminished to below significance after adjusting for the 
effects of pack-years and the interaction between Pi type and pack years. This would be 
consistent with a gene that exerted influence by altering susceptibility to smoke. 
Another approach to identify modifier genes is to select genes on the basis of known 
pathogenesis of COPD. Endothelial nitric oxide synthase has been thus studied and two 
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polymorphisms have been associated with more severe airflow obstruction in AATD 
which may suggest a modulatory function (Novoradovsky et al, 1999). 
Genome wide linkage studies, similar to those performed in usual COPD, in families of 
PiZ individuals may identify other putative genes in the future. Such studies may be 
improved by careful selection of a study population containing well characterised 
families with disparate lung function. 
1.2.6.8 Alpha-1-Antitrypsin Replacement Therapy 
Alpha-1-antitrypsin replacement therapy may be a logical choice for this condition and 
is a recognised treatment in some countries although is not currently used in the United 
Kingdom. Studies have adequately demonstrated that weekly or monthly infusions of 
AAT are safe and can increase plasma and lung fluid levels of AAT (Hubbard et al, 
1988; Wewers et al, 1987). However it is less clear whether this treatment holds any 
clinical benefit as, to date, any trials have been underpowered or not adequately 
controlled.  
One retrospective internet survey of patients suggested that patients receiving 
augmentation therapy had less exacerbations than those not receiving such therapy 
(Lieberman, 2000) but this observation needs to be tested in a prospective controlled 
trial. Seersholm et al have compared FEV1 decline in patients from Germany, where 
augmentation therapy is available, to patients from Denmark where it is not available 
(Seersholm et al, 1997). The German patients receiving therapy showed less decline in 
lung function although this effect was limited to patients with moderate airflow 
obstruction. In addition, a study of a single group of 96 patients before and after 
augmentation therapy showed a significant reduction in decline in FEV1 in a subgroup 
of patients with previous rapid decline, although this subpopulation contained only 7 
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individuals (Wencker et al, 2001). To date there has only been a single published 
randomised controlled trial of augmentation therapy with results suggesting that therapy 
may reduce emphysema progression as assessed by lung densitometry on CT scans 
(Dirksen et al, 1999). However this study included only 56 patients and the reduction 
seen did not achieve conventional levels of statistical significance. 
With the absence of supportive data for efficacy, alpha-1-antitrypsin replacement is not 
currently licensed for use in the United Kingdom. 
 
1.3 Exacerbations 
Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are an important 
feature of the disease and have a substantial effect on the morbidity and mortality from 
the disease. Exacerbations are heterogeneous in nature and aetiological agents include 
viruses, bacteria and air pollution. However the precise cause for a particular 
exacerbation in an individual is frequently not identified. The biology and impact of 
exacerbations has recently been reviewed (Celli et al, 2007; Hurst et al, 2007). 
Studies of exacerbations may be affected by the type of COPD population chosen due to 
the heterogeneous nature of the disease and other confounding factors. Furthermore the 
definition of an exacerbation used by investigators is an important consideration as 
there has not been a consistently used definition in clinical practice or in the research 
setting. 
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1.3.1 Definition of Exacerbations 
One definition of exacerbations that has been often used is based on criteria defined by 
the major symptoms of increased dyspnoea, sputum production and sputum purulence 
(Anthonisen et al, 1987). In addition, exacerbations defined by these criteria may be 
subdivided into three types: type 1 exacerbations are those with all major symptoms 
present; type 2 exacerbations occur when two of these symptoms are present; and type 3 
exacerbations show only one symptom. Minor exacerbation symptoms may also be 
present and these include fever, cough, wheeze, sore throat and nasal discharge. 
More recently a precise consensus definition has been reached which describes an 
exacerbation as “a sustained worsening of the patient's condition, from the stable state 
and beyond normal day-to-day variations, that is acute in onset and necessitates a 
change in regular medication in a patient with underlying COPD” (Rodriguez-Roisin, 
2000). It is likely that future studies on exacerbations will incorporate this consensus 
definition or other definitions. The ongoing INSPIRE study is using two parallel 
definitions: an event based exacerbation that requires use of healthcare resources and a 
separate symptom based definition (Seemungal et al, 2007). 
 
1.3.2 Exacerbations and Usual COPD 
Exacerbations are a common feature of usual COPD and place a large burden on 
National Health Service resources and expenditure (McGuire et al, 2001). Moreover, 
these episodes adversely affect patients and those with more frequent exacerbations 
have been shown to have worse quality of life (Seemungal et al, 1998) and are more 
likely to become housebound (Donaldson et al, 2005).  
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The precise incidence of exacerbations in usual COPD is difficult to quantify due to 
differences in definitions between patients, clinicians and researchers. Patients may not 
present to health care services with their exacerbations as they may be accustomed to 
changes in their symptoms and feel that medical intervention is not required. In the East 
London COPD Study of moderate-severe usual COPD patients, 49% of the 
exacerbations went unreported to the research team despite being noted on daily diary 
cards (Seemungal et al, 1998). The median exacerbation rate in this study, including 
episodes that were not directly reported, was 3 per patient per year.  
Some patients may consult their primary care physician at the time of exacerbations 
(Stockley et al, 2000) and more severe episodes may require hospitalisation. The usual 
treatment for exacerbations is empirical and includes increased β2-agonists, 
anticholinergic agents, oral steroids and antibiotics. Although the evidence to support 
each of these measures is inconsistent, patient recognition of an exacerbation and early 
intervention is associated with a more rapid recovery and a reduction in the need for 
hospitalisation (Wilkinson et al, 2004). 
 
1.3.3 Aetiology of Exacerbations 
The precise trigger for an individual exacerbation is often not identified. Even in the 
research setting this may be difficult as up to a third of stable COPD patients are 
colonised with bacteria at any one time which makes it difficult to be precise about the 
exact role of each pathogen during an exacerbation (Monso et al, 1995; Monso et al, 
1999). 
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1.3.3.1 Bacteria 
Common bacterial agents that may be isolated from sputum samples during 
exacerbations of COPD include Haemophilus influenzae, Streptococcus pneumoniae, 
Moraxella catarrhalis, H parainfluenzae and Pseudomonas sp. The proportion of 
patients with positive bacterial cultures increases during exacerbations and the bacterial 
load is usually much greater than that seen in the stable state which supports a bacterial 
aetiology, at least in a subset of exacerbations. In addition, increased bacterial load is 
associated with greater levels of inflammatory markers (Hill et al, 2000) and the type of 
bacterial species may also affect the degree of inflammation. Bacterial eradication has 
been shown to be associated with resolution of this increased inflammation (White et al, 
2003). However, those patients in whom bacteria continue to be cultured only have 
partial resolution of inflammation which may reflect continued stimulation by the 
reduced bacterial load. 
1.3.3.2 Viruses 
Viral agents may cause direct damage to the airways of COPD patients and may 
promote an inflammatory response. Furthermore viral infection may increase the risk of 
acquiring a secondary bacterial infection which may perpetuate or worsen an 
exacerbation. Viral agents that may be associated with exacerbations include 
Rhinovirus, Influenza, Parainfluenza, Respiratory Syncytial Virus and Adenovirus. 
Many studies have investigated the presence of viruses in COPD patients during 
exacerbations and suggest that up to a third of events are associated with viral infections 
(Greenberg et al, 2000; Seemungal et al, 2000b). However, one must consider that local 
epidemics, time of year, immunisation policy and disease severity may all confound the 
results of such studies. 
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1.3.3.3 Pollutants 
It is difficult to prove directly that air pollution is the cause of acute exacerbations and 
the mechanisms for any causal link are largely unknown. However, epidemiological 
studies have shown links between increases in pollutants (such as sulphur dioxide 
(SO2), nitrogen dioxide (NO2), ozone and particulate matter) and increased respiratory 
symptoms, medical intervention and mortality in COPD patients (Anderson et al, 1997; 
Garcia-Aymerich et al, 2000; Sunyer et al, 2000). It is estimated that up to 9% of 
hospital admissions due to COPD exacerbations may be caused by pollutants (Sunyer et 
al, 1993). 
 
1.3.4 Factors affecting the Frequency and Severity of Exacerbations 
Disease severity may affect the incidence of exacerbations and patients with more 
severe disease may have more frequent exacerbations. Furthermore the exacerbations 
may have a greater impact on patients with more severe disease and there may be more 
frequent medical care use, hospitalisation or even an increased likelihood of death in 
these individuals. 
Additional host factors may influence the susceptibility to exacerbations as some 
individuals have frequent episodes whilst others have none. Predictors for frequent 
exacerbations include symptoms of wheeze, cough and sputum production (Seemungal 
et al, 1998). One large prospective study of 5887 smokers with COPD showed that 
those patients with chronic bronchitis had more frequent infections than those without 
(Kanner et al, 2001). Patients with chronic bronchitis may have decreased mucociliary 
clearance (Mossberg et al, 1986) and reduced lung defences may facilitate bacterial 
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adherence, replication and subsequent invasion of the mucosa leading to an increase in 
exacerbations. 
This susceptibility to exacerbations persists as one predictor of frequent exacerbations is 
a previous history of frequent exacerbations (Ball et al, 1995; Seemungal et al, 1998). A 
mechanism for this increased susceptibility may be reduced defences including reduced 
proteinase inhibitor levels. Secretory leukoproteinase inhibitor (SLPI) is an important 
component of airways defence and has antiviral and antibacterial properties as well as 
proteinase inhibitor action. Levels of SLPI in sputum are significantly reduced in COPD 
patients with frequent exacerbations, even in the stable clinical state (Gompertz et al, 
2001). Whether reduced SLPI activity predisposes to increased frequency of 
exacerbations, either directly due to reduced antipathogen function or indirectly via 
uninhibited epithelial damage due to greater elastase activity, remains unknown. 
Reductions in other host defence mechanisms such as lysozyme may also play a role 
(Taylor et al, 1995). 
These host factors may be important in explaining some of the genetic susceptibility to 
COPD. Recently, familial aggregation of exacerbations has been noted (Foreman et al, 
2007) although these results may be influenced by other confounding factors such as 
passive tobacco smoke exposure. 
Environmental factors may also affect exacerbation frequency and a fall in indoor or 
outdoor temperature appears to be a risk factor (Donaldson et al, 1999). Whether this is 
related to increased viral infections or to other mechanisms is unclear. 
 
 31
1.3.5 Effect of Exacerbations on Lung Function  
One prospective study has closely assessed the effect of exacerbations on lung function 
(Seemungal et al, 2000a). In this study of 101 patients with moderate to severe COPD, 
504 exacerbations were recorded over a two and a half year period. Patients recorded 
daily morning peak expiratory flow rate (PEFR) and changes in respiratory symptoms 
on diary cards and a subgroup of 34 patients also recorded daily spirometry using a 
handheld device. Significant falls were seen in PEFR, FEV1 and FVC during 
exacerbations. Symptom changes during the episodes did not reflect those of lung 
function, but an increase in symptoms did predict some exacerbations, with dyspnoea or 
colds characterising the more severe episodes. The median time to recovery of peak 
flow was 6 days, although lung function recovery was incomplete in 7.1% of 
exacerbations at 91 days after the onset. This suggests that some episodes may 
contribute to deterioration in these parameters over time although further studies are 
required to support this hypothesis. 
Enhanced decline in lung function is well recognised in AATD (Group, 1998; Evald et 
al, 1990) and it has been suggested in a small study that exacerbation frequency may 
have an influence on this decline (Dowson et al, 2001a).  
It is therefore possible that interventions that reduce the frequency of exacerbations may 
also reduce decline in lung function. Inhaled corticosteroids have been shown to reduce 
the rates of exacerbation and the decline in health status in usual COPD, although they 
have not been shown to alter the decline in FEV1 (Burge et al, 2000; Jones et al, 2003). 
In addition, host factors such as the degree of airway obstruction may also be important 
as they have been shown to influence the treatment outcome of exacerbations (Dewan et 
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al, 2000) and thus may also influence the effect of exacerbations on other measures such 
as lung function. 
 
1.3.6 Exacerbations and Inflammation 
COPD is a condition in which, by the nature of its definition, there is an abnormal 
inflammatory response. During periods of exacerbation this background inflammatory 
process is increased although the precise mechanism remains unclear. The role and 
importance of inflammatory mediators during exacerbations appears to be complex and 
may vary between different clinical phenotypes within this disease.  
One study has shown a relationship between interleukin (IL)-8 and IL-6 levels in 
induced sputum samples during the stable clinical state and exacerbation frequency 
(Bhowmik et al, 2000). However the patients included in the study were an unselected 
group with no stratification for co-existing bronchiectasis, smoking status, severity of 
airflow obstruction and bacterial colonisation. In contrast, Gompertz et al found no 
significant difference in IL-8 levels when all of these parameters were accounted for 
(Gompertz et al, 2001). Such differences in characteristics of the study population, as 
well as differences in the definition of exacerbations and methodology, are seen in many 
studies on inflammation during COPD exacerbations. This can make comparisons and 
interpretation difficult. 
Histological studies on exacerbations are rare due to the difficulty in acquiring samples 
from symptomatic patients, particularly those with severe disease. However, two studies 
of bronchial biopsies during exacerbations have shown evidence of increased 
inflammation with recruitment of eosinophils and an increase in the numbers of CD4+ 
lymphocytes (Saetta et al, 1994; Zhu et al, 2001). 
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Exacerbations also lead to an increase in the numbers of neutrophils in the airways 
which is associated with the presence of or increase in sputum purulence (Stockley et al, 
2001). The colour of the sputum relates to the amount of myeloperoxidase present and 
has been shown to relate to the concentrations of the underlying markers of bronchial 
inflammation.  
The inflammation that occurs during an exacerbation is not limited to the lung 
parenchyma. Systemic inflammation is also seen as evidenced by a rise in C reactive 
protein (CRP) and serum IL-6 levels (Bhowmik et al, 2000; Stockley et al, 2000). 
Furthermore the time course of recovery of systemic inflammation after exacerbation is 
different between those who have frequent and infrequent exacerbations which suggests 
that CRP may be used as a predictor for future episodes (Perera et al, 2007). 
 
1.3.7 Exacerbations and AATD 
Exacerbations in patients with usual COPD are well documented but less is known 
about the occurrence, time course and effect of exacerbations in patients with alpha-1-
antitrypsin deficiency (AATD).  
However, the episodes are known to be associated with a greater degree of 
inflammation than in non-deficient patients (Hill et al, 1999a). At the start of an 
exacerbation, patients with AAT deficiency have lower sputum AAT, lower secretory 
leukoprotease inhibitor (SLPI) and higher elastase activity compared to COPD patients 
without deficiency, reflecting their deficient anti-proteinase defence. After treatment 
with antibiotics, there are significant changes in many sputum proteins including a rise 
in SLPI levels, and a reduction in myeloperoxidase (MPO) and elastase activity. 
Furthermore the sputum chemoattractants interleukin-8 (IL-8) and leukotriene B4 
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(LTB4) fall and protein leak (sputum/serum albumin ratio) reduces. These changes are 
rapid and provide good support to the advice that exacerbations in AATD should be 
treated promptly to minimise ongoing inflammation and consequent tissue damage. 
Exacerbations have a direct impact on patients with AATD and may also have an 
influence on the progression of disease over time. Thus it is important to investigate the 
effect of any therapies for this disease on the frequency and severity of exacerbations as 
well as other markers of disease severity. In order to include exacerbations as an end 
point in future trials, it is necessary to assess the occurrence and natural history of these 
episodes in this population.   
 
1.4 Health Status 
COPD is associated with a variety of symptoms which may vary between individuals 
and may change within an individual over time. The symptoms of COPD are not limited 
to the respiratory system and may include severe systemic effects. The symptoms of 
COPD, and their consequences for the individual, may have a tremendous impact on all 
aspects of a patients’ life including work, sports, recreation, home life, and activities of 
daily living. All of these effects may affect the patient’s quality of life. 
Maintaining a good quality of life is important for patients and many treatments for the 
condition aim to improve the patient’s symptoms and to reduce the adverse effect that 
these symptoms have on their well-being. The functional and psychosocial effects of 
COPD can have as great an impact on the individual as the physiological effects of the 
disease. Recognition of this has led to the development of a more scientific, 
standardised and objective way of quantifying how a person’s health status (or health-
related quality of life) is affected by their illness.  
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1.4.1 Health Status Measurements of Disease 
Health status measurements are taken by questionnaires which ask about the impact of 
the disease on symptoms, daily activities, physical ability, emotions and psychological 
well-being. Many questionnaires are available which vary in their length and 
complexity and different questionnaires emphasise different aspects of the impact of the 
disease. In order to be useful, health status tools should be validated in groups of 
patients to confirm repeatability and also to confirm the detection of differences 
between individuals. An ideal health status measurement should also be sensitive to 
changes within individuals over time. 
Disease-specific questionnaires have been developed with respiratory illness or COPD 
in mind and can be used for patients when assessing this particular disease. Generic 
questionnaires assess general health and may have more usefulness when comparing the 
impact of different illnesses on health. 
Health status measurements have become an important outcome measure for clinical 
trials as they are used to detect improvements in symptoms, physical functioning or 
other aspects of the patients’ quality of life. Disease-specific tools may be more useful 
in this context and may be more sensitive to the longitudinal change that would be 
assessed in interventional trials. However many trials use both a disease-specific 
measure and a generic measure to provide additional information and to aid comparison 
with other studies. Furthermore, health status measurements can be related to other 
measures of disease severity such as pulmonary function tests but the correlation 
between these measures and physiological tests is not strong and this confirms that they 
are assessing different aspects of the disease. However for a treatment or intervention to 
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be effective for patients, clinicians and researchers should look for improvements in 
symptoms and/or quality of life as well as improvements in other disease markers and 
these tools can be used to quantify any such changes. 
An important consideration when using these questionnaires for trial purposes is how to 
translate statistically important changes in health status into clinically significant 
changes for patients and their clinicians. Some instruments, such as the Chronic 
Respiratory Questionnaire (CRQ) (Guyatt et al, 1987a) and St George’s Respiratory 
Questionnaire (SGRQ) (Jones et al, 1992), have a validated threshold figure which 
equates to a clinically significant change and is useful when analysing the effect of a 
treatment on a group of patients over time. The usefulness of health status 
measurements on individual patients over time is less clear. However, clinically 
important thresholds can be translated back into the type of symptomatic or functional 
improvement required in an individual to change the score by that amount and these 
symptomatic or activity changes can then be elucidated through careful history taking. 
 
1.4.2 Health Status and COPD 
Physiological, functional, demographic and psychological factors may all affect health 
related quality of life in COPD. Some of these factors are also interrelated and they all 
may vary in their influence on health status between individuals and also within an 
individual over time.  Many health status instruments are designed to assess more than 
one aspect of COPD and so give an assessment of more than one of these factors. 
However, in general, it has been shown that health status measures correlate better with 
breathlessness scores than with physiological parameters such as FEV1. This reinforces 
that health status measures assess other aspects of COPD within individuals and can 
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complement the data obtained by physiological tests. Depression, anxiety and emotional 
dysfunction also have an important influence in COPD patients and will affect health 
status and its measurement. 
COPD patients show reduced health status compared to healthy subjects without COPD. 
Mahler et al used the generic Medical Outcomes Study questionnaire to assess the 
general health status of 110 stable but symptomatic male COPD patients who had no 
other significant comorbidity (Mahler et al, 1992). The same health status tool was used 
by Stewart et al to assess the health status of 11,186 patients from the general 
population who had visited a primary care physician or specialist (Stewart A.L et al, 
1988). Comparison of the two studies show that the patients with stable COPD  showed 
significantly lower scores, indicating worse health status, than the general patient 
population particularly for physical and role functioning. 
COPD patients have also been shown to have worse health status than patients with 
other diseases. In one study health status was measured in 50 COPD patients using the 
generic Short-Form 36 questionnaire and compared to the health status of 50 patients 
with unresectable non-small cell lung cancer (Gore et al, 2000). Patients with COPD 
showed worse health status than those with lung cancer and this was statistically 
significant for all of the SF36 components, apart from role emotional and role physical. 
 
1.4.3 Health Status and COPD Disease Parameters 
1.4.3.1 Pulmonary Function  
The most widely used physiological measure of COPD severity is the forced expiratory 
volume in one second (FEV1). Some studies have shown a correlation between this 
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measure and health status whilst others have shown no relationship. The demonstrated 
weak relationship between these measures implies that some individuals with severely 
impaired spirometry may maintain good health, whilst others with mild airflow 
obstruction may have a poor quality of life. 
1.4.3.2 Computed Tomography 
One small study of 22 patients with COPD and severe alpha-1-antitrypsin deficiency 
(PiZ phenotype) has investigated the relationship between the change in health status 
and the change in emphysema (Stolk et al, 2003). Health status was assessed in these 
individuals at baseline and at follow up at 30 months using the St George’s Respiratory 
Questionnaire which scores higher values for worse health status. Patients also had an 
assessment of the quantity of emphysema at these two time points using lung density 
measurements on spiral computerised tomography (CT) scans of the chest. The study 
showed a significant correlation between increasing emphysema, as quantified by lung 
density, and worsening health status, as measured by increasing SGRQ scores 
(Spearman correlation coefficient 0.60, p=0.003). Neither the changes in health status 
nor the changes in lung density correlated significantly with changes in forced 
expiratory volume in one second (FEV1) or changes in gas transfer (KCO) in this study. 
1.4.3.3 Exercise Capacity 
Health status has been shown to correlate with exercise capacity in COPD patients with 
AATD (Dowson et al, 2001b). A strong association was seen between a high SGRQ 
activity score (worse activity) and a low distance covered in the ISWT (Spearman’s 
correlation coefficient =-0.62, p<0.001). Other studies have shown a less strong 
relationship between health status measures and exercise capacity however this 
 39
relationship can vary depending on the subjects studied and the methods of assessment 
used. Alpha-1-antitrypsin deficiency patients often develop disease earlier than usual 
COPD and therefore have less comorbidity that accompanies aging, which may 
confound the relationship between exercise capacity and health status.  
 
1.4.4 Changes in Health Status 
Health status shows a demonstrable decline in COPD patients over time, although 
interventions may alter the rate of this decline. Patients in the ISOLDE study were 
randomised to receive either fluticasone propionate 500 μg twice daily or placebo for 3 
years and health status was assessed every 6 months over this time using the St 
George’s Respiratory Questionnaire (SGRQ) (Spencer et al, 2001). Health status 
declined progressively over the three years in a linear fashion. The placebo treated 
patients showed a decline in SGRQ Total score of 3.2 units per year (standard error 0.3) 
which is much greater than the annual decline of 0.12 units per year which seen in 
healthy people without COPD (Jones, 2001). The total SGRQ score has a clinically 
important threshold of 4 units and so the placebo treated COPD patients in this study 
showed a clinically significant decline in health status over 15 months. The fluticasone 
treated group in the ISOLDE study declined at a rate of 2.0 units per year (standard 
error 0.3) which was significant slower (p=0.004) than the placebo group but still 
equates to a clinically significant decline in these patients over a 2 year period.  
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1.4.5 Health Status and Exacerbations 
Frequent exacerbations has been shown to relate to worse health status as assessed by 
the St George’s Respiratory Questionnaire (SGRQ) (Seemungal et al, 1998). In this 
study, patients recorded the number of exacerbations of their COPD over a 12 month 
period: 32 patients had infrequent exacerbations (less than three) and 38 patients had 
frequent exacerbations (three or more), using the median number of exacerbations as the 
cut-off point. Patients who had frequent exacerbations over the previous 12 months 
showed significantly worse health status compared to patients with infrequent 
exacerbations (p≤0.003 for all components). This may suggest that strategies that lead to 
a reduction in the frequency of COPD exacerbations may improve well-being and 
quality of life. 
 
1.4.6 Health Status and Therapeutic Interventions 
1.4.6.1 Pharmacological Interventions 
Many studies that investigate therapeutic interventions now used health status 
measurement as an additional outcome measure. Health status measures can be used to 
identify improvements in symptoms or general health in these studies which is 
illustrated by the examples listed in Table 1. 
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Table 1 
Study Therapy/Intervention Effect on health status 
(Burge et al, 2000) • 500μg twice daily 
fluticasone 
• SGRQ showed less decline 
compared to placebo 
(Casaburi et al, 2002) • 18μg once daily 
tiotropium 
• SGRQ symptoms score improved 
(statistically and clinically) 
compared to placebo 
(Guyatt et al, 1987b) • Inhaled salbutamol  • Improvements in dyspnoea and 
fatigue domains of CRQ 
(Jones et al, 1997) • 50μg twice daily 
salmeterol for 16 
weeks 
• 100μg twice daily 
salmeterol for 16 
weeks 
 
• SGRQ significantly improved 
(statistically and clinically) 
compared to placebo 
• No change in SGRQ compared to 
placebo 
 
(Rossi et al, 2002) • Oral theophylline • Improvement in SGRQ Total score 
compared to baseline 
 
Effect of pharmacological therapies on health status in COPD. 
Furthermore the use of these instruments may also provide additional information as 
illustrated in the study by Jones et al (Jones et al, 1997). In this study, salmeterol use 
was associated with improvements in health status but these improvements were not 
seen in the patients who received the higher dose, as side effects from the drug were 
more prevalent and had an impact on health status. 
1.4.6.2 Non-pharmacological Interventions 
The effect of non-pharmacological interventions, such as pulmonary rehabilitation, on 
health status has been investigated widely in COPD patients. Lacasse et al have 
performed a meta-analysis of six randomised controlled studies of pulmonary 
rehabilitation and health related quality of life, most using the Chronic Respiratory 
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Questionnaire (Lacasse et al, 1996). Pulmonary rehabilitation in these studies was 
defined as exercise training for at least 4 weeks with or without psychological support, 
education or both and control groups in the studies received no rehabilitation. 
Significant improvements were seen in the dyspnoea and mastery domains of the CRQ 
in COPD patients who underwent pulmonary rehabilitation and these improvements are 
above the smallest difference perceived as important by the average patient. 
 
 
1.5 Clinical Trials in Alpha-1-Antitrypsin Deficiency 
Intravenous replacement of alpha-1-antitrypsin is a recognised treatment for deficient 
patients in the USA, Canada, Germany, Spain, Italy and Sweden. However clear 
evidence for the effectiveness of this treatment is absent, as there have been no 
conclusive controlled studies to demonstrate an influence on lung disease. Marketing 
and licence approval for the available intravenous therapies has been based on safety 
studies and biochemical data only. Furthermore intravenous treatment is often 
inconvenient for patients and alternative routes of drug administration, such as 
inhalation, have potential. It is hoped that any new product will be tested in a 
randomised controlled trial. 
Another approach for new therapies in this condition is to specifically target the 
emphysematous lung. Hyaluronic acid has been shown to be protective against elastase-
related damage in hamster models (Cantor et al, 1998). Moreover, reversal of 
pathological changes have been demonstrated in rat models of emphysema after 
administration of all-trans retinoic acid (Massaro et al, 1997). Such agents have 
potential as treatments for the whole COPD population. Evaluation of these therapies in 
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AATD patients has the benefit of a low incidence of co-morbidities as these patients 
tend to be younger than the usual COPD population.   
Modification of native AAT is another strategy to consider. The molecular 
polymerisation of Z protein within the liver has been well described and interruption of 
this process by the insertion of peptides may lead to release of protein into the serum 
and restoration of the anti-elastase protection.  
Finally genetic manipulation is another potential treatment option. Virus vectors have 
been used to insert the normal AAT gene into cells in animal models (Flotte, 2002). 
This approach in humans would improve serum levels of AAT but would not overcome 
the problems of polymerisation of abnormal protein. However gene repair technology 
will advance over the coming years and this may be an option in the future.  
Clinical trials of any new treatments will need to use defined outcome measures to 
assess an objective response. The effects of the treatment on the frequency and severity 
of exacerbations will be important. Furthermore the quality of life of the patients should 
be investigated alongside symptoms to assess the clinical impact of the treatment. These 
measures could be used alongside pulmonary function testing and emphysema 
quantification by CT scan. In order to use these measures as outcomes for trials, we 
must have clear evidence of these parameters outside the trial setting. Lung function 
deterioration and CT scanning has been adequately studied. However the nature and 
effect of exacerbations in this condition, as well as accurate information on the health 
status of AATD patients, must be investigated. In addition, any factors that may 
influence health status over time should be studied. The purposes of the current project 
were to investigate these features in a large group of AATD subjects. Furthermore 
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comparisons of lung function and health status were made between sibling pairs with 
severe deficiency. 
 
 45
2 AIMS 
The studies included in this thesis were performed to further define exacerbations, lung 
function and health status in patients with alpha-1-antitrypsin deficiency including 
sibling pairs. The aims were as follows: 
 
1) To investigate the frequency, duration, timing and nature of exacerbations and to 
identify host factors that may be associated. 
 
2) To investigate the impact of exacerbations on health related quality of life as 
measured by health status questionnaires. 
 
3) To investigate the changes in lung function and health status in patients with severe 
alpha-1-antitrypsin deficiency over time. 
 
4) To identify sibling pairs of patients with severe deficiency and to compare cross-
sectional lung function and health status. 
 
5) To study patients with discordant lung disease to identify factors that may influence 
the phenotypic expression of this disease. 
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3 GENERAL METHODS 
3.1 Patient Selection and Diagnosis 
3.1.1 Referral and Consent 
Patients were recruited from the ADAPT (Antitrypsin Deficiency and Assessment 
Programme for Treatment) project where the United Kingdom registry for AATD is 
held. This programme started in May 1996 and is funded by Bayer Corporation, USA. 
Subjects are referred to the registry by other health care professionals, largely chest 
physicians, from the whole of the UK. At the initial consultation a full family history is 
taken and family screening of first degree relatives is discussed. 
Assessment occurs annually and comprises collection of demographic data, clinical 
examination, pulmonary function testing, measurement of health status and computed 
tomography scanning where appropriate. The programme has been approved by South 
Birmingham Research Ethics Committee and by University Hospital Birmingham NHS 
Trust Research and Development Committee. Informed and written consent was 
obtained from all participating subjects and the consent form is included in Appendix 1. 
 
3.1.2 Diagnosis 
Serum alpha-1-antitrypsin levels were measured by immunoassay and all patients 
included in this work had a level of <11μM. All subjects also had PiZ phenotype 
identified by isoelectric focusing. Serum assays and phenotyping were both performed 
in a single laboratory in Heredilab, Salt Lake City, Utah, USA.  
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3.1.3 Demographic Data Collection 
At baseline, a full clinical history was taken to include respiratory symptoms, smoking 
history and the presence of chronic bronchitis (Medical Research Council, 1965). 
Smoking exposure was quantified in pack years which were calculated as the number of 
cigarettes smoked per day, divided by 20, and then multiplied by the number of years of 
smoking. Patients were classified as index cases if their symptoms had led to the 
diagnosis of AATD and non-index if they were diagnosed through family screening. 
None of the subjects received alpha-1-antitrypsin replacement therapy. 
 
3.2 Lung Function Testing 
All lung function tests were performed at least four weeks after any exacerbation. 
Predicted values were calculated using the equations from the British Thoracic 
Society/Association of Respiratory Technicians and Physiologists guidelines for 
respiratory function (1994). All tests were performed according to standard operating 
procedure by trained respiratory physiologists within the Lung Investigation Unit, 
University Hospital Birmingham, Birmingham, UK. 
 
3.2.1 Spirometry and Reversibility Testing 
Spirometry was measured using wedge bellows (Vitalograph Ltd, Buckinghamshire, 
UK) and both forced and relaxed manoeuvres were performed. At the first visit each 
subject performed spirometry before and after nebulised 5mg β2 –agonist and 500 μg 
ipratropium bromide (Dowson et al, 2001b). Positive bronchodilator reversibility was 
taken to be an increase in FEV1 of greater than 200ml and greater than 12% predicted 
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(Quanjer et al, 1993). At subsequent visits, spirometry was repeated after dual 
bronchodilatation and changes in lung function were derived from all post-
bronchodilator values. 
 
3.2.2 Lung Volume Measurements 
Lung volume measurements were assessed using helium dilution as first described in 
1949 (Meneely et al, 1949). The Benchmark system was used (Morgan Medical, Kent, 
UK). After correct positioning each patient was asked to breathe at tidal volumes and 
the initial concentration of helium was recorded. Following tidal expiration, the patient 
was connected to the helium circuit and continued to breathe tidally. The concentration 
of helium was measured every 30 seconds until stable. Finally the patient performed 2 
relaxed expiratory residual volume/ inspiratory vital capacity manoeuvres followed by 2 
relaxed expiratory vital capacity manoeuvres in sequence.  
Static lung volumes including total lung capacity (TLC) and residual volume (RV) were 
calculated from the measurements taken. All volume measurements were subsequently 
corrected to Body Temperature and Pressure Saturated with water (BTPS) using the 
appropriate correction factor. 
 
3.2.3 Gas Transfer Measurements 
Gas transfer measurements were obtained by the single breath carbon monoxide method 
(Blakemore et al, 1957) using the Benchmark system ( Morgan Medical, Kent, UK). 
After a small breath in, patients were requested to expire as far as possible to aim to 
reach residual volume. After full inspiration (to at least 90% of relaxed vital capacity) 
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patients were asked to hold their breath, without straining, for 10 seconds. This was 
followed by full expiration to collect both washout and sample gas. 
Transfer factor (TLCO) was calculated in units of mmol/min/kPa to represent the rate of 
uptake of gas per pressure gradient. The uptake of gas per unit of effective alveolar 
volume, KCO, was also calculated. 
 
3.3 Health Status Measurements 
Two health status questionnaires were used to assess health-related quality of life. Data 
was recorded at each visit before lung function testing and prior to contact with a 
physician. No reference to previous answers was made during follow up visits. 
 
3.3.1 St George’s Respiratory Questionnaire  
The St George’s Respiratory Questionnaire (SGRQ) (Jones et al, 1992) was used as a 
disease specific tool with a high score indicating worse health status and a clinically 
important change in total score being greater than four points (Jones et al, 1997; Jones, 
2002; Jones, 2002). This self-administered questionnaire consists of 50 items and is 
included in Appendix 2. Each questionnaire response has a unique empirically derived 
weight with the lowest possible weight as 0 for the best possible patient and the highest 
as 100 for the worst possible patient. Three component scores are calculated 
(symptoms, activity and impacts) as well as a total score. Each component score is 
calculated by dividing the summed weights for that component by the maximum 
possible weight for that component and is expressed as a percentage.  The total score is 
calculated in a similar manner. Missing items in the symptoms component are treated as 
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negative answers. For blank answers in the activity and impacts components, the item is 
coded as missing and the weight for that item is subtracted from the total possible 
weight for that component and from the total weight. 
 
3.3.2 Short-Form 36 
The Short-Form 36 (SF36) was used as a generic health status questionnaire (Brazier et 
al, 1992). The SF36 is a standardised, self-administered tool that assesses eight 
components of health. These components can be combined to produce 2 summary 
scores (Physical and Mental). Missing items are calculated using an algorithm if the 
respondent answered at least half of the items within that component. Each component 
score is transformed into a percentage of the total possible score for that component. A 
low score indicates worse health status and to date no threshold for a clinically 
significant change has been validated. The SF36 is included in Appendix 3. 
 
3.4 Computed Tomography 
Computed Tomography (CT) scans of the chest were acquired using a General Electric 
Prospeed scanner (General Electric Medical Systems, Milwaukee, Wisconsin, USA). A 
high resolution protocol was employed and images were obtained at 10mm intervals 
with the patient lying supine and at full inspiration. All scans were reported by a single 
radiologist with a specialist interest in lung disease. The presence of emphysema was 
documented according to published guidelines (Naidich, 1991). 
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3.5 Statistics 
Data were analysed using SPSS version 11. Parametric data are displayed as mean with 
standard error (SE) and non-parametric data as median with interquartile range (IQR). 
Repeated measures at two time points were compared using the Wilcoxon signed rank 
test. Subgroup comparisons were made using the Mann-Whitney U test for two groups 
and Jonckheere-Terpstra test for three and four groups. Pearson’s coefficients were used 
for correlations between continuous variables and frequency comparisons were made 
using the χ2 test. Binary logistic regression was used to test for independent predictors 
of exacerbations and stepwise linear regression to identify independent factors 
associated with changes in lung function parameters and health status. Statistical 
significance was accepted as p < 0.05. 
Changes in lung function tests over three years were calculated using linear regression 
on the four measurements taken over that time and then converted into a change per 
year. Similar calculations were performed to obtain values for health status changes. 
Linear regression was performed on a larger set of 408 PiZ patients to calculate the 
effect of smoking on FEV1. From the resultant equation, a predicted value was 
calculated for each sibling based on the smoking history of the individual. The actual 
FEV1 value measured was then compared to the predicted value to calculate a residual 
value for each patient: a low value indicating a worse FEV1 than predicted. 
 
3.6 Author Contribution 
The current work was made possible through the work of all of the team members of the 
ADAPT project. Patient recruitment and clinical data collection was performed by me 
and other physicians working on the project. Lung function testing was performed by 
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the trained technicians from the Lung Investigation Unit. Nurse team members 
performed the health status questionnaires before any physician contact but I performed 
the subsequent health status calculations. I collated the clinical, exacerbation, 
pulmonary function and health status data to create new databases for the analyses in 
this thesis. All calculations and statistical analysis was performed solely by me, as was 
the writing of this thesis. 
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4 EXACERBATIONS AND HEALTH STATUS 
4.1 Introduction 
Although exacerbations in patients with usual COPD have been reasonably well 
documented, less is known about exacerbations in alpha-1-antitrypsin deficiency and 
the effect of exacerbations on health status and disease progression. In order to design 
and power relevant clinical trials in AATD, more detailed information concerning the 
number, nature, timing and consistency of exacerbations is required. It is also important 
to identify any host factors that may be associated with these episodes.  
Health status questionnaires are frequently used to assess the quality of life of patients 
with Chronic Obstructive Pulmonary Disease (COPD). COPD is associated with 
reduced health related quality of life, which is related, in part, to FEV1. However little is 
known about the change in health status over time and the relationship to changes in 
lung function.  
Many clinical trials now include health status as a valid outcome measure and so an 
understanding of how exacerbations may affect health status and the change in health 
status over time is also important. 
 
4.2 Methods 
4.2.1 Subjects 
The first 265 patients with PiZ deficiency recruited to the UK registry from 1996 were 
studied. Patients were assessed at an initial baseline visit and full demographic data was 
collected. Further assessment was made at 12 months for all patients. Ninety patients 
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were assessed annually for a further 2 years. One subject underwent lung transplantation 
during this time and was removed from the three year analysis. Two patients continued 
to smoke during this follow up period and were also removed from the analysis to 
maximise patient homogeneity. 
4.2.2 Exacerbation Data 
On visits, after initial baseline visit, details of the occurrence and nature of 
exacerbations of respiratory symptoms over the previous year were obtained during 
patient interview. The length and time of year of the first four episodes were noted from 
patient recall, with corroboration from diary cards where possible. Exacerbations were 
defined as acute episodes of worsening symptoms and were categorised according to the 
Anthonisen classification (Anthonisen et al, 1987). Type 1 exacerbations were defined 
as those with increased dyspnoea, sputum volume and sputum purulence. Type 2 
exacerbations occurred when two of these symptoms were present and type 3 
exacerbations when only one symptom was present. The duration of the exacerbation 
was taken as the length of time from the onset of worsening symptoms up to the last day 
before the patient was back to their usual state of health. Frequent exacerbations were 
defined as 3 or more episodes over a 12 month period. The incidence of exacerbations 
was documented annually for the patients who were followed for 3 years. 
 
4.2.3 Lung Function Testing 
Full lung function tests were performed at each annual visit as described in the general 
methods 3.2 (Section 3.2). All tests were performed at least 4 weeks after any 
exacerbation to minimise any temporary effect on these values. 
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Changes in lung function measurements over 3 years were calculated using linear 
regression on the four measurements taken for each individual over that time. This 
result was then converted into a change per annum. 
 
4.2.4 Health Status 
Health status measurements were made at each annual visit using the SGRQ and the   
SF-36. No reference to previous answers was made during data collection. 
Annual changes were calculated from linear regression of the four values obtained over 
the three years. 
 
4.3 Results 
4.3.1 Subjects studied for 1 year 
4.3.1.1 Baseline Characteristics 
Of the 265 PiZ patients, 167 (63%) were male and 210 (79%) were index cases. One 
hundred and eighty four patients (69%) were ex-smokers and 17 (6%) continued to 
smoke during the first year. Chronic bronchitis was diagnosed in 110 (42%) patients. 
One hundred and forty six patients used inhaled steroids consistently throughout the 
initial 12 month period. Thirteen patients had steroid therapy changed during this 12 
month period and were removed from the analysis related to the influence of inhaled 
corticosteroids. The baseline characteristics of the whole group are shown in Table 2.  
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Baseline characteristics for the whole patient group, patients with and without 
exacerbations over the first year and for the subgroup followed for 3 years. Data 
presented as mean ± standard deviation or median (interquartile range). NS: not 
significant; * univariate comparison of those with and without exacerbations; # t 
test; † Chi squared test; all other statistical comparison uses Mann Whitney U test. 
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Table 2  
 
 
All patients 
 
 
Patients with no 
exacerbations 
over year 1 
Patients with ≥1 
exacerbation 
over year 1 
p value* Subgroup 
studied for 3 
years 
Number of subjects 265 123 142  87 
Age (years) 49.9 ± 9.8 50.0 ± 11.1 49.9 ± 9.5 NS# 50.2 ± 9.3 
Body mass index (kg/m2) 25.0 (22.9-27.8) 25.1 (23.2-27.8) 24.8 (22.2-27.8) NS 25.0 (23.0-27.0) 
Smoking history (pack years) 13.0 (1.4-24.0) 12.0 (0.5-22.8) 14.6 (4.0-26.0) NS 17.5 (0-25.0) 
Smoking status 
Current 
Ex 
Never 
 
17 
187 
61 
 
8 
84 
31 
 
9 
103 
30 
 
NS† 
 
0 
65 
22 
Gender  
Male 
Female 
 
167 
98 
 
80 
43 
 
87 
55 
 
NS† 
 
59 
28 
Presentation 
Index 
Non Index 
 
210 
55 
 
90 
33 
 
120 
22 
 
0.023† 
 
67 
20 
Chronic bronchitis 
Yes 
No 
 
110 
155 
 
39 
84 
 
71 
71 
 
0.003† 
 
35 
52 
Inhaled steroid in year 1 
Yes 
No 
Altered  
 
146 
106 
13 
 
56 
64 
3 
 
90 
42 
10 
 
0.002† 
 
47 
37 
3 
Bronchodilator reversibility 
Yes 
No 
 
65 
198 
 
23 
100 
 
42 
98 
 
0.034† 
 
23 
63 
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4.3.1.2 Exacerbations 
During the first year of study, exacerbations occurred in 142 subjects (54%) and 47 
(18%) had frequent exacerbations as defined by three or more episodes (Seemungal et 
al, 1998). One patient described 30 exacerbations over twelve months and was excluded 
from the analysis. The median number of exacerbations for the whole group was 1 (IQR 
0-2), although for those patients who experienced at least one exacerbation the median 
number was 2 (IQR 1-3). Eighty nine patients had type 1 exacerbations, 44 had type 2 
exacerbations, 2 had both type 1 and type 2 exacerbations and 7 patients had type 3 
exacerbations during this year. 
Exacerbations were experienced throughout the year but were more frequent in the 
winter months, with 32% of episodes occurring in December and January as shown in 
Figure 1. 
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Figure 1 
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The proportion (%) of exacerbations occurring in each month of the year. Exacerbations are categorised by Anthonisen criteria 
into type 1 (dark grey), type 2 (light grey) and type 3 (white). 
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Episodes varied in length from 2 to more than 35 days as illustrated in Figure 2. The 
median length of each episode was 14.0 days (IQR 7-21). 
 
Figure 2 
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The length of the exacerbations of symptoms is illustrated with the proportion of 
the total (%) shown for each time period. Exacerbations are categorised by 
Anthonisen criteria into type 1 (dark grey), type 2 (light grey) and type 3 (white). 
 
4.3.1.3 Exacerbations and Baseline Characteristics 
Exacerbations occurred more frequently in those patients with chronic bronchitis (1.7 ± 
0.2 vs 1.2 ± 0.2, χ2: p<0.001). Index patients were more likely to have exacerbations 
compared to non-index patients (1.6 ± 0.2 vs 0.8 ± 0.2, χ2 : p=0.016). There was no 
relationship between the number of exacerbations and age, gender or body mass index. 
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However, a weak correlation was seen between the number of pack years smoked and 
the number of exacerbations (r=0.12, p=0.03).  
Furthermore, patients using inhaled steroids consistently throughout the twelve months 
had more exacerbations than those who were consistent non-users (χ2 : p=0.004) as did 
those with bronchodilator reversibility (χ2 : p=0.042).  
 
Univariate comparisons of baseline characteristics of those with and without 
exacerbations are displayed in Table 2 (page 57). 
 
4.3.1.4 Lung Function 
Lung function data was obtained from 259 patients as 6 did not wish to undergo testing. 
Measurements ranged from normal to severe airflow obstruction and markedly impaired 
gas transfer. Data obtained at the start of the study and at twelve months are included 
for completion: baseline data are summarised in Table 3 alongside univariate 
comparisons of baseline lung function of those with and without exacerbations; Table 4 
shows the lung function data after one year together with comparisons between those 
with and without exacerbations.  
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Table 3 
 
 
n All patients 
 
 
Patients with 
no 
exacerbations 
over year 1 
Patients with 
≥1 
exacerbation 
over year 1 
p 
value
* 
FEV1 (L) 
259 1.53  
(1.02-2.45) 
1.77  
(1.11-2.93) 
1.42  
(0.98-2.16) 
0.005 
FEV1  
(% predicted) 
259 46.2  
(33.8-76.8) 
55.2  
(35.6-95.3) 
43.3  
(32.9-68.5) 
0.013 
VC (L) 259 4.13  
(3.16-4.99) 
4.28  
(3.66-5.11) 
3.97  
(2.85-4.92) 
0.049 
VC  
(% predicted) 
259 103.5  
(91.4-117.3) 
106.9  
(95.6-119.9) 
101.7  
(87.6-115.9) 
0.044 
FEV1/VC (%) 259 39.5 
(28.2-58.8) 
42.2 
(28.4-73.8) 
36.5 
(27.3-52.4) 
0.002 
RV (L) 250 2.58  
(2.04-3.24) 
2.51  
(2.00-3.16) 
2.72  
(2.18-3.42) 
0.037 
RV  
(% predicted) 
250 129.7  
(102.6-155.1) 
126.1  
(99.7-148.9) 
137.4  
(106.7-173.8) 
0.008 
TLC (L) 250 7.40  
(6.06-8.40) 
7.38  
(6.20-8.54) 
7.47  
(5.91-8.37) 
NS 
TLC  
(% predicted) 
250 119.0  
(107.4-130.5) 
118.4 
(107.7-128.1) 
119.1 
(108.1-132.6) 
NS 
RV/TLC (%) 250 36.4  
(29.4-43.0) 
34.3  
(28.0-41.5) 
38.9  
(32.4-45.5) 
0.002 
TLCO 
(mmol/min/kPa) 
256 6.37  
(4.65-8.27) 
6.60  
(4.99-8.46) 
5.86 
 (4.29-7.85) 
0.035 
TLCO   
(% predicted) 
256 68.0  
(52.0-85.0) 
72.0  
(55.0-88.0) 
63.6  
(50.0-83.0) 
0.055 
KCO 
(mmol/min/kPa/L) 
256 1.08  
(0.80-1.39) 
1.12  
(0.80-1.44) 
1.00  
(0.78-1.35) 
NS 
KCO 
(% predicted) 
256 67.9  
(53.7-86.0) 
69.0  
(55.0-87.0) 
66.2  
(51.0-85.7) 
NS 
 
Lung function values at baseline for the whole patient group and patients with and 
without exacerbations over the first year. Data presented as mean ± standard error 
or median (interquartile range). NS: not significant; * univariate comparison of 
those with and without exacerbations using Mann Whitney U test. 
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Table 4 
 
 
n All patients 
 
 
Patients with 
no 
exacerbations 
over year 1 
Patients with 
≥1 
exacerbation 
over year 1 
p 
value*
FEV1 (L) 
259 1.49  
(0.97-2.31) 
1.66  
(1.04-2.78) 
1.41  
(0.96-2.06) 
0.008 
FEV1  
(% predicted) 
259 46.6  
(33.0-74.9) 
52.6  
(35.2-94.8) 
43.0  
(31.6-65.7) 
0.014 
VC (L) 259 4.08  
(3.19-4.97) 
4.42  
(3.58-5.13) 
3.79  
(2.95-4.83) 
0.005 
VC  
(% predicted) 
259 104.3  
(90.7-118.5) 
107.9  
(97.3-122.3) 
102.5  
(86.3-113.1) 
0.004 
FEV1/VC (%) 259 38.0 
(27.8-57.9) 
42.3 
(26.9-73.3) 
36.2 
(28.1-49.1) 
0.003 
RV (L) 242 2.66  
(2.02-3.28) 
2.51  
(1.90-3.28) 
2.70  
(2.19-3.32) 
NS 
RV  
(% predicted) 
242 127.5  
(103.2-162.9) 
123.7  
(96.0-150.0) 
132.3  
(107.7-170.2) 
0.013 
TLC (L) 242 7.24  
(6.16-8.62) 
7.20  
(6.20-8.71) 
7.26  
(6.01-8.51) 
NS 
TLC  
(% predicted) 
242 118.7  
(107.7-131.0) 
118.3  
(107.1-130.0) 
119.9  
(108.0-131.5) 
NS 
RV/TLC (%) 242 37.5  
(29.9-44.1) 
34.2  
(28.3-42.5) 
38.8  
(32.9-45.8) 
0.004 
TLCO 
(mmol/min/kPa) 
250 6.22  
(4.57-8.08) 
6.40  
(4.66-8.25) 
6.07  
(4.42-7.93) 
NS 
TLCO   
(% predicted) 
250 66.0  
(50.0-82.0) 
68.0  
(51.0-84.5) 
65.0  
(50.0-81.0) 
NS 
KCO 
(mmol/min/kPa/L) 
250 1.02  
(0.79-1.37) 
1.09  
(0.80-1.38) 
1.01  
(0.78-1.32) 
NS 
KCO 
(% predicted) 
250 66.2  
(52.0-84.0) 
68.1  
(53.0-85.1) 
65.1  
(52.0-83.0) 
NS 
 
Lung function values at year 1 for the whole patient group and patients with and 
without exacerbations over the first year. Data presented as mean ± standard error 
or median (interquartile range). NS: not significant; * univariate comparison of 
those with and without exacerbations using Mann Whitney U test. 
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Patients with more severe airflow obstruction, as defined by GOLD criteria (Pauwels et 
al, 2001), had more frequent exacerbations (Jonckheere-Terpstra : p=0.002) over the 
study period as demonstrated in Figure 3.  
 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
The bubble plot shows the number of exacerbations over the first 12 months in 
patients grouped according to their GOLD stage. Open circles indicate each data 
point. Solid circles show the mean for each stage, horizontal line is the 75th centile,  
and the cross indicates the median value. The lower 25th centile was zero for all 
stages. Significantly more exacerbations are seen in those patients with greater 
airflow obstruction (Jonckheere-Terpstra: p=0.002). 
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Binary logistic regression was performed using all of the patient demographic data, lung 
function data and smoking history. The presence of chronic bronchitis, bronchodilator 
reversibility and increased air trapping, as measured by RV/TLC, were all independent 
predictors of exacerbations (estimated r2=0.13). For those patients with exacerbations, 
greater body mass index, female gender, increasing age and lower FEV1 were all 
predictors of type 1 exacerbations (estimated r2=0.17). 
 
4.3.1.5 Health Status 
Health status scores also showed a wide variation at baseline and are summarised in 
Table 5 together with univariate comparisons of those with and without exacerbations. 
Health status measurements at year 1 are shown in Table 6. 
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Table 5 
 All patients 
 
 
Patients with 
no 
exacerbations 
over year 1 
Patients with 
≥1 
exacerbation 
over year 1 
p 
value* 
n 263 121 142  
SGRQ     
Total 51.6  
(31.5-65.3) 
45.3  
(25.1-58.2) 
55.4  
(38.0-68.7) 
<0.001 
Symptoms 64.0  
(44.1-78.8) 
57.7  
(36.8-72.6) 
70.9  
(53.6-83.8) 
<0.001 
Activity 66.2  
(41.4-85.9) 
59.5  
(35.2-79.7) 
72.8  
(48.5-92.6) 
<0.001 
Impacts 36.8  
(20.0-52.5) 
31.8  
(14.7-46.3) 
41.5  
(25.2-56.8) 
<0.001 
SF-36     
Physical 37.7  
(28.9-45.9) 
40.5  
(32.6-49.7) 
34.0  
(26.7-42.5) 
<0.001 
Mental 53.2  
(45.2-58.7) 
53.3  
(46.4-58.8) 
53.1  
(42.5-58.5) 
NS 
 
Health status scores at baseline for the whole patient group and patients with and 
without exacerbations over the first year. Data presented as mean ± standard error 
or median (interquartile range). NS: not significant; * univariate comparison of 
those with and without exacerbations using Mann Whitney U test. 
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Table 6 
 
 All patients 
 
 
Patients with 
no 
exacerbations 
over year 1 
Patients with 
≥1 
exacerbation 
over year 1 
p 
value* 
n 262 122 140  
SGRQ     
Total 49.5 (31.0-64.0) 42.0 (22.2-57.3) 56.4 (39.2-70.2) <0.001 
Symptoms 60.7 (38.8-75.0) 40.3 (20.1-61.6) 70.8 (59.0-81.7) <0.001 
Activity 66.2 (41.4-87.2) 57.3 (35.5-79.7) 73.0 (47.9-92.5) <0.001 
Impacts 36.4 (18.7-52.3) 28.2 (13.6-46.2) 40.9 (25.2-55.6) <0.001 
SF-36     
Physical 36.7 (28.3-45.4) 39.4 (31.2-48.7) 34.4 (26.2-43.8) 0.001 
Mental 54.8 (47.5-59.2) 55.4 (48.6-59.2) 54.2 (46.0-59.3) NS 
 
Health status scores at year 1 for the whole patient group and patients with and 
without exacerbations over the first year. Data presented as mean ± standard error 
or median (interquartile range). NS: not significant; * univariate comparison of 
those with and without exacerbations using Mann Whitney U test. 
 
 
A clear relationship was seen between the number of exacerbations and SGRQ total 
score at year 1 (r=0.41, p<0.001) as shown in Figure 4. A correlation was also seen 
between the exacerbation number and SF36 physical score (r=-0.33, p<0.001) as seen in 
Figure 5. 
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Figure 4 
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The boxplots show SGRQ total score at month 12 in patients with no (white), 
infrequent (light grey) and frequent (dark grey) exacerbations. Thick black lines 
show the median values, boxes are interquartile ranges, whiskers show the total 
range and circles are outliers. Higher scores, indicating worse health status, are 
found in patients with infrequent exacerbations and even higher in those with 
frequent exacerbations (Jonckheere-Terpstra: p<0.001) compared to those patients 
without episodes. 
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Figure 5 
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The boxplots show the SF36 physical score at month 12 in patients with no (white), 
infrequent (light grey) and frequent (dark grey) exacerbations. Thick black lines 
show the median values, boxes are interquartile ranges, whiskers show the total 
range and circles are outliers. Lower scores, indicating worse health status, are 
seen in patients with infrequent exacerbations and even lower in those with 
frequent exacerbations (Jonckheere-Terpstra: p<0.001) compared to those without 
episodes. 
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Patients with more severe airflow obstruction (GOLD criteria) had worse SGRQ health 
status scores and SF36 physical component scores (all p<0.001). SGRQ Total scores are 
shown in Figure 6.  
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The boxplots show the SGRQ Total score at month 12 in patients grouped 
according to their GOLD stage. Thick black lines show median values, boxes are 
interquartile ranges, whiskers show the total range and circles indicate outliers. 
Significantly worse scores are seen in those patients with greater airflow 
obstruction (Jonckheere-Terpstra: p<0.001). 
 
Linear regression of SGRQ total scores at month 12 showed that lower FEV1, number 
of exacerbations, increasing age, increase in pack year smoking history and the presence 
of chronic bronchitis were all independent factors associated with worse SGRQ total 
score and together accounted for 54% of the overall variability in the score. 
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4.3.2 Subjects Studied for 3 Years 
The baseline characteristics of this subgroup are shown in Table 2 (page 55). Fifty nine 
patients (68%) were male, 67 (77%) were index cases and 65 (75%) were ex-smokers.  
 
4.3.2.1 Lung Function Progression 
The lung function data obtained at baseline and year 3 are summarised in Table 7. 
FEV1 values showed a significant decline (p<0.001) with a median change of                 
-41ml/year (IQR –96 to -15) over 3 years which reflects an average change of 57ml/year 
(SE ± 7.5).  A frequency histogram showing annual change in absolute FEV1 values is 
shown in Figure 7.  
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Table 7 
 
 n Base Year 3 Annual change 
FEV1 (L) 87 1.57 
(1.00-2.43) 
1.32 
(0.88-2.22) 
-0.041 
(-0.096 to -0.015) 
FEV1 
(% predicted) 
87 48.5 
(33.1-87.8) 
41.6 
(31.1-81.5) 
-1.0 
(-2.5 to 0.1) 
VC (L) 87 4.09 
(3.25-4.83) 
3.90 
(3.29-4.71) 
-0.052 
(-0.120 to 0.006) 
VC  
(% predicted) 
87 105.3 
(94.5-120.5) 
106.2 
(87.1-122.9) 
-0.5 
(-2.2 to 1.4) 
FEV1/VC 
(%) 
87 40.8 
(26.7-60.8) 
38.2 
(25.7-55.0) 
-0.9 
(-2.1 to 0.2) 
RV (L) 81 2.52 
(2.00-3.24) 
2.70 
(2.05-3.37) 
0.064 
(-0.034 to 0.172) 
RV  
(% predicted) 
81 126.5 
(97.0-154.8) 
133.7 
(101.8-169.7) 
1.7 
(-3.3 to 7.9) 
TLC (L) 81 7.28 
(6.14-8.22) 
7.21 
(6.02-8.46) 
0.029 
(-0.117 to 0.148) 
TLC  
(% predicted) 
81 118.9 
(104.7-132.1) 
117.4 
(105.8-134.2) 
0.5 
(-1.9 to 2.4) 
RV/TLC (%) 81 35.5 
(29.2-42.3) 
39.5 
(30.5-44.8) 
0.6 
(-0.3 to 2.0) 
TLCO 
(mmol/min/kPa) 
87 6.24 
(4.67-8.32) 
5.39 
(4.11-7.16) 
-0.21 
(-0.37 to -0.04) 
TLCO   
(% predicted) 
87 66.0 
(53.0-88.0) 
61.0 
(46.5-80.5) 
-1.8 
(-3.6 to -0.2) 
KCO 
(mmol/min/kPa/L) 
87 1.06 
(0.77-1.41) 
0.99 
(0.72-1.33) 
-0.03 
(-0.05 to 0) 
KCO  
(% predicted) 
87 67.2 
(53.3-91.8) 
64.5 
(46.5-85.8) 
-2.0 
(-3.7 to -0.7) 
 
The lung function data at baseline and the end of year 3 are shown together with 
the change per year and the number of patients tested at the two time points. All 
values were post-bronchodilator measurements. The annual change was calculated 
from a linear regression analysis of four measurements over 3 years for each 
individual patient. All values shown are median values with interquartile range in 
parentheses. 
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Figure 7 
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Frequency histogram of annual absolute change in FEV1. Annual change was 
calculated from a linear regression analysis of four measurements over 3 years for 
each individual patient. Grey bars illustrate lung function decline and open bars 
represent measured improvement in FEV1. 
 
Residual volume measurements and air trapping (as measured by RV/TLC ratio) 
showed significant increases (p<0.001) over the 3 year period whereas gas transfer 
measurements showed a significant decline (p<0.001). A frequency histogram showing 
annual change in absolute KCO values is shown in Figure 8. 
 
 74
Figure 8 
0
5
10
15
20
25
30
1 2 3 4 5 6 7 8 9 10 11
Annual change in KCO (mmol/min/kPa/L)
N
um
be
r o
f p
at
ie
nt
s
More -0.10 -0.08 -0.06 -0.04 -0.02 0 0.02 0.04 0.06 0.08
 
Frequency histogram of annual absolute change in KCO. Annual change was 
calculated from a linear regression analysis of four measurements over 3 years for 
each individual patient. Grey bars illustrate lung function decline and open bars 
represent measured improvement in KCO. 
 
4.3.2.2 Health Status Change 
 
Health status values measured at baseline and year 3 are summarised in Table 8. Over 
the 3 year period, there was no significant change in SGRQ total score, activity score 
and impact score or in the SF36 scores. However, the SGRQ symptom score showed a 
significant improvement (p=0.003) over this period of time with a median change of      
-2.0 units/year (IQR -6.2 to +1.6). 
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Table 8 
 n Base Year 3 Annual Change 
SGRQ     
Total 86 52.5 (27.8-66.6) 50.0 (29.3-67.7) -0.5 (-2.2 to 1.4) 
Symptoms 86 66.4 (37.5-84.3) 61.4 (37.9-74.3) -2.0 (-6.2 to 1.6) 
Activity 86 61.1 (35.5-86.6) 69.6 (36.2-92.5) 0.2 (-1.3 to 2.5) 
Impacts 86 39.3 (17.7-54.5) 34.0 (16.2-54.0) -0.1 (-2.4 to 1.9) 
SF-36     
Physical 86 39.7 (28.8-47.6) 34.6 (29.1-47.6) -0.4 (-2.2 to 1.1) 
Mental 86 52.3 (42.6-57.8) 55.0 (46.7-59.3) 0.5 (-1.1 to 2.3) 
 
The health status scores at baseline and the end of year 3 are shown together with 
the change per year and the number of patients tested at the two time points. The 
annual change was calculated from a linear regression analysis of four 
measurements over 3 years for each individual patient. All values shown are 
median values with interquartile range in parentheses. 
 
This improvement in SGRQ symptom score was shown to be progressive over the three 
years in the 76 individuals who completed all four time points in the annual assessment 
as shown in Figure 9. 
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Figure 9 
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The boxplots show the SGRQ Symptom score at four annual time points in 76 
patients. Thick black lines show median values, boxes are interquartile ranges and 
whiskers show the total range. Significant reduction in scores relating to 
improvement in symptoms is seen progressively year on year (Freidmans p=0.028). 
 
4.3.2.3 Exacerbations over 3 Years 
The mean number of exacerbations reported for all patients was 1.0 (±0.2) in the first 
year, 1.3 (±0.2) in year 2 and 1.2 (±0.2) for year 3. The proportion of patients having 
exacerbations remained consistent over the three years and patients with exacerbations 
in the first year were more likely to continue having exacerbations in year 2 (p=0.04) 
and year 3 (p<0.001). At least one exacerbation had occurred in 50.6% of patients in the 
first year, 75.9% by year 2 and 80.5% by year 3. Frequent exacerbations (more than 2 
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episodes per year) were seen in 12.6% of patients in the first year, 19.0% in year 2 and 
13.8% in year 3.  
 
4.3.2.4 Exacerbations, Changes in Lung Function and Changes in Health Status 
Neither the presence nor the frequency of exacerbations over the 3 years showed a 
relationship to the absolute decline in FEV1 or FEV1 expressed as a % predicted. 
Furthermore, exacerbations did not have an effect on the decline in FEV1 when patients 
were grouped according to baseline airflow obstruction (GOLD criteria). However, a 
weak but significant correlation was seen between frequency of exacerbations and 
decline in TLCO as a % predicted (r=-0.19, p=0.037).  
 
Greater improvement in SGRQ symptom score was seen in those patients who had 
infrequent or no exacerbations (p=0.029) (Figure 10).  
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The boxplots show the annual change in SGRQ symptom score in patients with no 
(white), infrequent (light grey) and frequent (dark grey) exacerbations. Thick 
black lines show the median values, boxes are interquartile ranges, whiskers show 
the total range and circles are outliers. Greater improvement is seen in patients 
with fewer exacerbations (Jonckheere-Terpstra: p=0.029). 
 
When patients were grouped according to baseline airflow obstruction (GOLD criteria), 
no significant differences in the change in health status were seen between the groups. 
 
Worsening SGRQ activity score was, however, related to the decline in FEV1 (r=-0.24, 
p=0.015) and to decline in VC (r=-0.23, p=0.017). Finally, although the total score did 
not change, a significant correlation was also seen between the changes in SGRQ total 
score and increased air trapping as measured by the RV/TLC ratio (r=0.20, p=0.037). 
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4.3.2.5 Linear Regression of Changes in Lung Function 
Linear regression showed that bronchodilator reversibility and lower body mass index at 
baseline were both independently associated with a greater decline in FEV1 (% 
predicted) and together accounted for 14% of the overall variability in the decline. An 
increasing number of exacerbations was the only independent factor associated with a 
greater decline in TLCO (% predicted) but accounted for only 5% of the variability in 
this decline. 
 
4.4 Discussion 
These results have demonstrated that exacerbations occur commonly in patients with 
AATD and a third of the patients with exacerbations (18% of the total group) had 3 or 
more episodes per year. The average number of exacerbations for the whole group was 
similar to that seen in non AATD COPD in general (Seemungal et al, 1998). The 
presence and frequency of exacerbations remained consistent from year to year and, 
although exacerbations occur throughout the year, nearly one third occurred in 
December and January. The median length of symptoms in these patients is 14 days 
which, despite being based largely on patient recall, is similar to the duration 
determined prospectively by diary cards in a group of subjects studied previously (Hill 
et al, 1999a). The length of these exacerbations is greater than the 7 days seen in usual 
COPD (Seemungal et al, 2000a) although the current study used different methods for 
data collection. Taken together, these data suggest that AATD alone does not 
predispose to exacerbations but may influence their resolution. 
At the start of patient recruitment in 1996 there was no consensus about the definition of 
an exacerbation, which has subsequently been more precisely defined to include a 
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change in regular medication as has been suggested subsequent to the commencement 
of our study (Rodriguez-Roisin, 2000). Nevertheless, the overall frequency is similar to 
that seen in COPD in general, when this more rigorous definition is applied, suggesting 
that the data are equally valid.  
There is a potential for recall bias when the patients were asked about their 
exacerbations during the previous year. This was minimised, where possible, by 
comparison with diary cards of symptoms. Patient recall data on exacerbations in this 
group of patients has also been corroborated with patient records in a previous more 
limited study that gave similar results (Dowson et al, 2002). Thus the current results are 
likely to be an accurate representation of the number and nature of exacerbations in 
AATD when obtained by this method. It should be considered however that the actual 
number of episodes may be higher than reported here. Studies on exacerbations in usual 
COPD using diary cards show that up to 49% of exacerbations may remain 
unrecognised or unreported by patients (Perera et al, 2007; Seemungal et al, 1998; 
Seemungal et al, 2000a). Thus any future studies should carefully consider how recall 
and report bias may underestimate these episodes. 
The population used was an unselected group of subjects with severe AATD and thus 
the patients showed a range of lung function from normal to severe impairment. 
The patients included in the 3 year analysis study were all non-smokers or ex-smokers 
and the small number of continuing smokers was excluded to maximise patient 
homogeneity. Thus this data cannot be extrapolated to patients with AATD who 
continue to smoke. Patients who continue to smoke may show a greater decline in lung 
function measurements and the effect that this has on health status is unknown. 
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Chronic mucus hypersecretion has been shown to be associated with increased 
likelihood of exacerbations in usual COPD (Miravitlles et al, 2000) and in AATD 
(Dowson et al, 2002). In the current study, 42% of the patients had chronic bronchitis 
and these patients showed an increased frequency of exacerbations, confirming previous 
findings (Dowson et al, 2002). 
Although index patients had more exacerbations than non-index patients in the 
univariate analysis, index status was not independently related to exacerbations in the 
multivariate analysis. Index patients had a greater smoking history and a lower baseline 
FEV1 and patients with more severe airflow obstruction had more frequent 
exacerbations, which probably accounts for the initial association with index status. It 
should be noted that half of the patients in the most severe group as grouped by airflow 
obstruction had no exacerbations. This may be due to survivorship bias. Some of these 
more severely affected patients may not return to research programmes or may die 
during an exacerbation. Thus the data from subjects who do return for further testing 
may be from a “select” group who, perhaps, have remained free of exacerbations. 
In addition, increased air trapping as measured by residual volume was also shown to be 
associated with exacerbations. The reason for this is unknown but increased air trapping 
would increase the work of breathing and may, therefore, lead to a greater awareness of 
slight pathophysiological changes that increase this work further and be reflected in the 
awareness of increased breathlessness. Alternatively, the exacerbations themselves may 
damage the small airways leading to an increase in air trapping. At present, it remains 
unknown whether this is a cause or effect but the observed relationship between FEV1 
decline and exacerbation frequency in usual COPD (Donaldson et al, 2002) is more 
supportive of a direct effect. It remains unknown why this is not reflected in a change in 
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FEV1 in AATD. However there are changes in TLCO which suggest that exacerbations 
do play a role in the impairment of lung physiology.  
Bronchodilator reversibility was also associated with exacerbations and this may reflect 
a change in the reversible component of airways function during such episodes. In the 
current study, the immediate effect of an exacerbation on spirometry and reversibility 
was not investigated because of patient distance from the centre, but other studies have 
shown some correlation between symptoms of dyspnoea and a temporary reduction in 
peak flow measurements (Seemungal et al, 2000a).  
Exacerbations were associated with the use of an inhaled steroid. However, the current 
study was not designed as an interventional study and this observation may reflect the 
practice of prescribing inhaled steroids more often in patients with frequent 
exacerbations or in those with lower lung function. 
Exacerbations were shown to have an influence on health status scores which supports 
data obtained by other groups (Doll et al, 2002; Seemungal et al, 1998). For the SGRQ 
symptom score this reflects the fact that two of the component questions ask about “the 
number and length of attacks of chest trouble”. However, worse health status was also 
reflected in the other individual components and total score of the SGRQ as well as the 
components of the SF36 in those patients with exacerbations. This association was not 
due to a difference in lung function alone as exacerbations were found to have an 
additional independent effect on health status scores using regression analysis. In 
addition, other factors such as increasing age, chronic bronchitis, and increase in pack 
year smoking history as well as reduced FEV1 were all shown to have independent 
effects on health status scores irrespective of exacerbations. This confirms that quality 
of life as measured by these questionnaires is affected by many factors other than 
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physiological impairment and that improvement in health status measures is potentially 
achievable by using several diverse therapeutic strategies. The suggestion that 
augmentation therapy reduces exacerbations (Lieberman, 2000) may therefore be an 
important therapeutic aim in patients with alpha-1-antitrypsin deficiency. 
During previous work on a small number of subjects, Dowson et al (Dowson et al, 
2001a) demonstrated that improvements in SGRQ symptom score occur in patients 
attending for review at the UK specialist clinic over 2 years. The current study shows 
that this improvement is progressive and is sustained in a larger group of patients over a 
longer period of time and reflects a change that is recognisable by the patients. This 
improvement is greater in patients with fewer exacerbations.  
Of more importance, the overall health status did not decline despite major changes in 
lung function (mean FEV1 decline of 171 ml over the 3 years). Miravitlles et al have 
also shown an improvement in SGRQ symptom score in a cohort of non-AATD COPD 
patients despite worsening activity (Miravitlles et al, 2004). Other data in usual COPD 
shows a decline in health status with an increase in SGRQ total score of 9.6 points over 
3 years when the FEV1 falls by 177 ml although a lesser change of 6.0 points occurs in 
patients on inhaled steroids with a mean FEV1 decline of 150ml (Burge et al, 2000; 
Spencer et al, 2001). Since the patients in the current study showed a similar decline in 
FEV1, it would be expected that the SGRQ should also change by at least this amount. 
Recently, Stolk et al have demonstrated a worsening of SGRQ  score in 22 patients with 
AATD over 30 months with a mean change of 6.5 units (-2.9-17.5). The lack of 
significant change in overall health status in the current cohort, despite documented 
deterioration in lung function and activity may reflect as yet undefined benefits of the 
specialist clinic in which patients are seen on an annual basis in the UK. Inhaled steroid 
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treatment was not altered significantly in these patients over the study period. However 
other therapeutic measures, such as the use of long-acting β-agonists, an alternative 
management strategy for the treatment of infections and improved patient education 
may have played a role in the maintenance of health status over the 3 year period. 
It is confirmed that lung physiology measurements deteriorate in these patients over 
time. The decline in spirometric values is not related to the frequency of exacerbations 
in the whole group or in patient subgroups defined by severity of FEV1 impairment. 
This is contrary to the findings of Donaldson et al in usual COPD (Donaldson et al, 
2002). However, other workers have suggested that only smokers are susceptible to an 
influence of exacerbations on FEV1 decline (Kanner et al, 2001) and the patients in the 
3 year study reported here were all ex-smokers or non-smokers. It is also possible that 
exacerbations have a less clear deleterious effect on FEV1 in AATD patients than in 
usual COPD patients due to the increased ongoing inflammation in the stable state. The 
FEV1 decline was, however, associated with greater bronchodilator reversibility at 
baseline as has been seen previously (Dowson et al, 2001a; Group, 1998) and this may 
be due to an increase in airway inflammation contributing to both airways 
hyperreactivity and subsequent structural changes in the airways.  
An association of low BMI with FEV1 decline is seen in the current study but it is not 
clear if this reflects an increased risk or represents a consequence of established disease. 
It has been suggested that a low BMI in men may increase the risk of development of 
COPD (Harik-Khan et al, 2002) but how this relates to patients with another risk factor 
such as AATD is not known. 
The decline in TLCO was associated with the number of exacerbations. The proposed 
pathogenic mechanism for the development of emphysema and decreased gas transfer in 
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AATD is related to an increased neutrophilic elastase burden along with reduced 
protection due to low alpha-1-antitrypsin levels. An increase in elastase challenge is 
seen during periods of exacerbations especially in AATD (Hill et al, 1999a) but this is 
only a feature of purulent exacerbations. In this study, the majority of exacerbations 
were classified as type 1, which, by definition, includes purulent sputum as a feature. 
Thus increased elastase activity should be present in most of these episodes and may 
lead to further tissue destruction and reduction in the gas transfer ability of the lungs. 
However, it should be noted that such episodes were not related to the decline in KCO. 
The TLCO reflects not only alveolar gas exchange but also regional gas distribution 
which will be influenced by small airways damage. Exacerbations are more likely to be 
related to infection and inflammation in the airways than in the alveoli. Thus, such 
episodes may have more effect on the small airways and any subsequent structural 
change would lead to altered distribution of ventilation thereby reducing the TLCO but 
not the KCO. 
The patients in the current work were followed for 3 years. Although this length of time 
is comparable to that in many observational and interventional studies in COPD, it may 
be too short to reliably estimate changes in lung function. More reliable estimates of 
changes in lung function measures may be achieved by following patients for 10 or 
more years (Burrows et al, 1986; Lebowitz et al, 1975). Longer longitudinal studies can 
account for survey bias, learning effects and non-linearity of lung function change. 
However these studies can be difficult to achieve with large numbers of subjects and 
also may under-represent severe disease due to a survivor effect of less severe patients 
continuing in the study. 
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More recently other pulmonary function measures including operating lung volumes 
have been incorporated into COPD and exacerbation studies. Acute exacerbations are 
associated with lung hyperinflation as well as worsening airflow obstruction and 
measuring inspiratory capacity is one way to assess this. It has been shown that 
improvements in inspiratory capacity relate to reduction in dyspnoea during the 
recovery from exacerbation (Parker et al, 2005; Stevenson et al, 2005) and that 
inspiratory capacity improves at a faster rate than FEV1 (Pinto-Plata et al, 2007). The 
relationship between inspiratory capacity and exacerbations over time remains unclear. 
Interpretations of individual pulmonary function measures may be difficult and hard to 
transpose into meaningful benefits for patients and so combined measures may be more 
useful. Cote et al have shown that exacerbations negatively impact on the BODE index 
(body mass index, obstruction, dyspnoea and exercise capacity) (Cote et al, 2007) and 
future studies may benefit from using these patient-centred outcomes.  
Alpha-1-antitrypsin augmentation therapy may lessen the decline in lung function in 
AATD, as has been suggested by some workers (Wencker et al, 1994) . Lieberman has 
hypothesized that augmentation therapy may also reduce the frequency and severity of 
infections in AATD on the basis of patient opinion on the effect of their treatment 
(Lieberman, 2000). Prospective controlled studies are therefore needed to investigate 
these hypotheses further and future trials of antiprotease replacement should include 
exacerbations as an important outcome measure. If a reduction in exacerbations can be 
achieved with augmentation therapy, the data suggests it should also influence quality 
of life and decline in lung function, although not necessarily the decline in FEV1. The 
current study provides a firm basis upon which to design, power and implement such 
trials. 
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5 SIBLINGS 
5.1 Introduction 
Adult patients are primarily diagnosed with alpha-1-antitrypsin deficiency after 
presentation to health services with respiratory symptoms (index patients). However the 
alpha-1-antitrypsin genes are inherited in an autosomal co-dominant fashion and thus 
siblings of an index PiZ patient, who share heterozygote parents, have a 1 in 4 chance of 
having the same genotype and may be detected by family screening (non-index 
subjects). Index patients have been shown to have more severe airflow obstruction than 
non-index patients (Silverman et al, 1989), although differences in these populations 
may be influenced by ascertainment bias and differences in smoking. Nevertheless, 
investigation of heterozygote relatives of PiZ individuals suggests that undetermined 
familial factors may contribute to lung disease expression in this disease (Silverman et 
al, 1990a; Silverman et al, 1990b). 
Sibling pairs with this deficiency have not been widely studied although case reports  of 
individual sibships have suggested that the lung disease of PiZ siblings may be 
discordant (Apprill et al, 1990; Stableforth, 1978). In this section of work a group of 
sixty sibling pairs have been studied. Comparisons of lung function data, health status 
measurements and CT scans were made between index and non-index siblings, as well 
as baseline demographics. 
In addition, a larger group of patients were analysed to estimate the impact of smoking 
on spirometric values. A correction factor based on an individual’s smoking history was 
devised and applied to the values obtained from the sibling pairs in order to determine 
whether any difference between pairs can be explained by a smoking effect.  
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Finally a subset of 6 pairs of non-index siblings was analysed separately to counteract 
any ascertainment bias. 
5.2 Methods 
5.2.1 Subjects 
Sixty sibling pairs with severe alpha-1-antitrypsin deficiency (PiZ) were studied. 
A full clinical history was taken to include respiratory symptoms, smoking history and 
the presence of chronic bronchitis as defined by MRC criteria (Medical Research 
Council, 1965). Patients were classified as index siblings if their symptoms had led to 
the diagnosis of alpha-1-antitrypsin deficiency being made and non-index patients if 
they were diagnosed through family screening of the index case. Six families contained 
more than one PiZ sibling identified through family screening and these non-index pairs 
were analysed separately to overcome any potential ascertainment bias. 
 
5.2.2 Lung Function Testing 
Lung function tests were performed as described in Section 3.2. Patients performed 
dynamic spirometry after dual bronchodilatation with nebulised β2–agonist and 
ipratropium bromide. Lung volume measurements were taken using helium dilution 
(Morgan Medical, Kent, UK) and gas transfer measurements by the single breath carbon 
monoxide method. One patient did not perform any lung function tests and thus data 
from 59 sibling pairs in total were analysed. 
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5.2.3 Health Status 
Health status comparisons were made in the index/non-index pairs. The St George’s 
Respiratory Questionnaire (SGRQ) was used as a disease specific tool with a high score 
indicating worse health status and was completed by 51 pairs. The generic Short-Form 
36 (SF36) was also used with a low score indicating worse health status and 52 pairs 
completed this questionnaire.  
 
5.2.4 CT scanning 
The index/non-index pairs were also assessed using computed tomography (CT) 
scanning of the chest to identify the presence or absence of emphysema (Naidich, 
1991). The scans were reported by a single radiologist. The quantity and distribution of 
emphysema was not analysed in this study. Seven patients from the whole group did not 
have a CT scan performed, most commonly because they had recently received a recent 
CT scan at another centre. 
 
5.2.5 Smoking Correction Factor 
Linear regression was performed on a larger set of 408 PiZ patients to calculate the 
effect of smoking on FEV1. The FEV1, as percent of predicted, was regressed against 
smoking expressed in pack years. From the resultant equation, a “new” predicted value 
was calculated for each sibling based on the smoking history of the individual. The 
measured FEV1, as expressed as percent of predicted, was then compared to the “new” 
predicted value to calculate a residual value for each patient: a low value indicating a 
worse FEV1 than predicted. 
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5.3 Results 
5.3.1 Patient Characteristics  
 
Patient characteristics of the 54 pairs of index and non-index siblings are shown in 
Table 9. 
 
Table 9 
 Index  
Sibling 
Non-Index  
Sibling 
p value 
Age (years) 
 
46.9  
(41.4-53.6) 
44.4  
(37.1-52.9) 
NS* 
Body mass index (kg/m2) 
 
24.6  
(22.3-27.2) 
26.7  
(24.4-29.7) 
0.016* 
Smoking history (pack years) 
 
14.4  
(4.9-24.0) 
7.2  
(0-15.0) 
NS* 
Smoking status        
Current 
Ex 
Never 
 
7 
37 
10 
 
9 
29 
16 
 
NS# 
Gender       
Male 
Female 
 
31 
23 
 
35 
19 
 
NS# 
Chronic Bronchitis     
Yes 
No 
 
26 
28 
 
22 
32 
 
NS# 
Inhaled Steroid 
Yes 
No 
 
34 
20 
 
13 
41 
 
<0.001# 
Emphysema on CT scan 
Yes 
No 
 
44 
5 
 
25 
27 
 
<0.001# 
 
Patient characteristics of index and non-index siblings. Values given as median 
(IQR).* Wilcoxon signed rank test; # χ2 test. CT scanning was not performed in 
five index and two non-index subjects. 
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There was no significant difference in age, gender, presence of chronic bronchitis or 
baseline smoking status between the index and non-index siblings. The index patients 
had smoked more than non-index cases as a whole group (14.4 pack years [IQR 4.9-
24.0] vs 7.2 [IQR 0-15.0]; p=0.039, Mann-Whitney U), although this was not 
significant when the two groups were compared as pairs (p=0.085, Wilcoxon signed 
rank test). 
Index patients had a median body mass index (BMI) of 24.6 (IQR 22.3-27.2) which was 
significantly lower than the BMI of non-index sibling at 26.7 (IQR 24.4-29.7) (p=0.016, 
Wilcoxon signed rank test). More index patients were prescribed an inhaled steroid 
compared to their non-index siblings (p<0.001, χ2 test). 
Analysis of the 101 patients who had undergone CT scanning showed a 4.0 fold 
increase in relative risk of having emphysema on the scan if the patient had ever 
smoked. Index siblings (n=49) were more likely to have evidence of emphysema on CT 
scan (44 with emphysema: 5 without) compared to non-index siblings (n=52) (25 with 
emphysema: 27 without) (p<0.001, χ2 test).  
 
5.3.2 Lung Function Data 
5.3.2.1 Index-Non-index Pairs 
Lung function measurements taken from the patients ranged from normal to severe 
airflow obstruction and markedly impaired gas transfer. Data are listed in Table 10. 
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Table 10 
 n Index  
Sibling 
Non-Index  
Sibling 
p value* 
FEV1, (L) 53 1.31  
(1.00-2.20) 
2.34  
(1.74-4.05) 
<0.001
FEV1  
(% predicted) 
53 42.4  
(28.1-69.6) 
82.9  
(52.8-116.1) 
<0.001
VC, (L) 53 3.80  
(3.23-4.79) 
4.43  
(3.67-5.60) 
0.003
VC  
(% predicted) 
53 99.4  
(83.8-113.7) 
110.0  
(97.6-124.4) 
0.007
FEV1/VC (%) 53 37.8 
(28.3-50.0) 
63.5 
(43.9-80.4) 
<0.001
RV, (L) 51 2.71  
(2.23-3.59) 
2.03  
(1.73-2.70) 
0.002
RV  
(% predicted) 
51 136.9  
(110.5-194.6) 
109.6  
(89.6-129.4) 
0.001
TLC, (L) 51 7.45  
(5.74-8.32) 
7.12  
(6.06-8.07) 
NS
TLC  
(% predicted) 
51 119.3  
(110.3-133.4) 
114.2  
(107.0-114.2) 
0.033
RV/TLC, (%) 
 
51 39.9  
(29.7-48.7) 
31.7  
(24.9-41.9) 
<0.001
TLCO, 
(mmol/min/kPa) 
50 5.85  
(4.38-8.43) 
7.79  
(6.77-10.07) 
<0.001
TLCO   
(% predicted) 
50 62.1  
(51.0-85.5) 
84.5  
(72.5-105.0) 
<0.001
KCO, 
(mmol/min/kPa/L) 
50 1.09  
(0.76-1.34) 
1.40  
(1.10-1.61) 
<0.001
KCO  
(% predicted) 
50 69.1  
(48.3-87.4) 
82.8  
(70.9-101.3) 
<0.001
Bronchodilator 
reversibility 
Yes  
No 
 
 
52 
 
 
18 
34 
 
 
11 
41 
NS#
 
Lung function data of index and non-index siblings with paired statistical 
comparison of the 2 groups. Values given as median (IQR). * Wilcoxon signed 
rank test, # χ2 test. 
 
The number of patients in each group as categorised by GOLD stage (Fabbri et al, 
2003) is illustrated in Figure 11.  
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Figure 11 
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The numbers of index (white) and non-index siblings (grey) are shown categorised 
by GOLD stage (Fabbri et al, 2003). A significant proportion of non-index patients 
have airflow obstruction but this is less severe than the index cases. 
 
Thirty one (58%) of the siblings diagnosed through family screening had evidence of 
airflow obstruction on testing (FEV1/FVC<70%) and 25 (47%) patients in this group 
had an FEV1 which was less than 80% predicted. However, paired comparisons 
between the two groups showed that the index siblings had a significantly lower FEV1, 
lower carbon monoxide transfer factor (TLCO), lower gas transfer per unit volume (KCO) 
and greater residual volume/total lung capacity ratio (RV/TLC) than their siblings (all 
p<0.001). Index siblings also showed higher RV and TLC expressed as % predicted 
than their relatives (p=0.001 and p=0.033 respectively). There was no significant 
difference in bronchodilator reversibility between the pairs. 
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There was no correlation between the FEV1 (Figure 12), VC or RV values (% predicted) 
of the index and non-index siblings.  
 
Figure 12 
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The scatter plot shows the FEV1 of the sibling pairs expressed as % predicted. No 
correlation exists between the index and non-index siblings. 
 
However the 2 groups showed a significant correlation of KCO (r=0.49, p<0.001) 
(Figure 13), TLCO (r=0.47, p=0.001), TLC (r=0.34, p=0.017) % predicted values and 
RV/TLC ratios (r=0.33, p=0.02) (Figure 14). One patient had a markedly low gas 
transfer due to a combination of emphysema and thromboembolic disease but removal 
of this outlying subject from the analysis did not alter the significance of the correlation 
of gas transfer values between the pairs. 
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Figure 13 
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The scatter plot shows the KCO of the sibling pairs expressed as % predicted. A 
significant correlation is seen between the index and non-index siblings.  
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Figure 14 
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The scatter plot shows the RV/TLC ratio of the sibling pairs. A significant 
correlation is seen between the index and non-index siblings.  
 
5.3.2.2 Non-index-Non-Index Pairs 
Six pairs of non-index siblings were analysed separately. There was no significant 
correlation between these pairs for FEV1 (Figure 15) or gas transfer (p=0.152 and 
p=0.551 respectively).  
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The scatter plot shows the FEV1 of the non-index sibling pairs expressed as % 
predicted. No significant correlation is seen between the siblings identified through 
family screening. 
 
5.3.2.3 Correction for Smoking 
Linear regression showed that the number of pack years smoked was a significant 
variable associated with FEV1 in a core group of 408 PiZ patients. The linear equation 
estimated an average reduction in FEV1 of 1.2% of the predictive value per pack year 
smoked. This figure was used to calculate a predicted FEV1 for each sibling based on 
their personal smoking history. This calculated value was subtracted from the measured 
FEV1 (% predicted) value to obtain a residual figure. Comparison of these residual 
figures between siblings showed no significant correlation (Figure 16). Thirty sibling 
pairs showed “discordance” with one sibling having a worse FEV1 than predicted and 
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the other a better FEV1 than predicted after correction for smoking (illustrated by open 
circles in Figure 16). 
Figure 16 
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The scatter plot shows the residual FEV1 value of the sibling pairs. The residual 
FEV1 was calculated by subtracting the predicted FEV1 for each individual (based 
on the smoking history) from the measured FEV1. Negative values show a 
measured FEV1 that is worse than predicted and positive values a value that is 
better than predicted based on the smoking history. No significant correlation is 
seen between the index and non-index siblings after this correction for smoking 
differences. Discordant sibling pairs are shown by open circles and concordant 
siblings by closed circles. 
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5.3.3 Health Status Data 
Health status scores also showed a wide variation and index patients had worse SGRQ 
scores and SF36 Physical scores than their siblings (all p<0.001). Health status scores 
are shown in Table 11. 
 
Table 11 
 
 n Index  
Sibling 
Non-Index  
Sibling 
p value* 
SGRQ 51   
Total  53.6 (39.8-69.4) 34.0 (11.5-55.1) <0.001
Symptoms  75.7 (61.0-86.1) 50.9 (23.8-73.6) <0.001
Activity  72.8 (53.5-92.5) 47.3 (11.9-72.8) <0.001
Impact  39.9 (28.5-54.2) 25.9 (5.8-46.1) <0.001
SF-36 52   
Physical  38.1 (24.6-44.3) 45.1 (35.0-53.5) <0.001
Mental  53.4 (43.3-58.7) 53.3 (49.1-58.8) NS
 
Health Status scores of index and non-index siblings with paired statistical 
comparison of the 2 groups. Values given as median (IQR). * Wilcoxon signed 
rank test. 
 
5.4 Discussion 
The current work investigates sibling pairs with severe alpha-1-antitrypsin deficiency. 
The data shows that siblings identified through family screening of a proband also have 
a significant risk of lung disease. However the degree of impairment in these cases is on 
average less severe than that seen in the index patients. 
It is possible that ascertainment bias may have influenced the current results. It is not 
surprising that index patients show significant disease, as these patients have usually 
been tested for AATD after presentation with respiratory symptoms and signs. It is 
 100
known that many people with AATD remain undiagnosed and that restricted testing for 
the condition influences the detection rate and types of patients diagnosed (Hill et al, 
1999b). Thus some selection bias will have influenced the current study population. 
However the results are fully representative of the patients that present in respiratory 
practice.  
Index siblings had lower body mass index, higher inhaled corticosteroid use, and worse 
health status than their non-index siblings. All of these measures probably reflect the 
more severe disease seen in the index cases. This is consistent with previous studies 
comparing groups of unpaired index patients and non-index subjects identified by other 
methods (Silverman et al, 1989). 
There may also be some selection bias in the non-index siblings who are identified, 
despite the current practice to offer testing to all siblings of index cases that present to 
the UK registry. PiZ relatives who experience symptoms may perhaps be more likely to 
accept the offer for testing than PiZ relatives who remain symptom-free, which may 
explain the high incidence of disease in the identified siblings. Forty seven percent of 
the non-index PiZ siblings in this study had a FEV1<80% predicted which is greater 
than the 29% of affected cases seen in siblings of usual COPD patients (McCloskey et 
al, 2001). Moreover, this high incidence of lung disease provides further support for 
screening in these families to enable smoking prevention or cessation advice to be given 
to susceptible family members, as well as management of exacerbations and symptoms 
where appropriate (American Thoracic Society et al, 2003). 
An important observation is that no correlation in FEV1 values is seen between the two 
groups even when values were adjusted for differences in personal smoking history. 
Furthermore, this discordance was also seen in the pairs of non-index siblings identified 
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by family screening who would not be affected by ascertainment bias, although the 
study numbers were small. Taken together, these results suggest that there is another 
factor or factors that vary between these sibling pairs that influences the susceptibility 
of lung disease. This could be a factor that increases the risk of one sibling or indeed a 
factor that has a protective effect on the less severely affected sibling. Genome scanning 
and linkage studies in usual COPD patients have identified genetic loci that may 
influence spirometric measures and lung function change (Gottlieb et al, 2001; Joost et 
al, 2002; Wilk et al, 2003). These or other genetic modifiers may also influence the risk 
of COPD development in AATD and these “discordant” siblings would be an important 
group to investigate further through molecular studies with this concept in mind.  
On the other hand, this study has shown that gas transfer values do correlate between 
the pairs, indicating physiological concordance for this measure despite differences in 
spirometric values. This may suggest that the different phenotypes of parenchymal 
disease and airway disease may be affected by alternate subsets of genes which 
influence the underlying pathological changes. Alternatively, the parenchymal disease 
may be more closely related to the alpha-1-antitrypsin deficiency itself and less affected 
by modifier genes. These hypotheses provide a sound background for further genetic 
investigation of sibling pairs with AATD in the future. 
Smoking remains the most important risk factor for the development and progression of 
lung disease in AATD (Seersholm et al, 1995; Seersholm et al, 1998) and some of the 
putative genes that influence lung function may do so by altering the susceptibility to 
smoke. Silverman et al have shown that the increased risk of airflow obstruction in 
relatives of early-onset usual COPD patients is restricted to smokers alone (Silverman et 
al, 1998). Whether this is also the case in AATD patients is unclear, although some 
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lifetime non-smokers do develop airflow obstruction (Janus et al, 1985; Seersholm et al, 
1998). It would be of importance to determine whether the same is true of other 
physiological changes such as gas transfer. 
In summary, the current work emphasises that other factors other than cigarette smoke 
contribute to the development of COPD or its phenotype in AATD patients and their 
families. These factors may include other genes, environmental exposures and gene-
environment interactions. Sibling pairs with this condition, particularly those with 
discordant disease or concordant parenchymal disease, are an ideal group of patients to 
further investigate the influence of other candidate genes. 
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6 DISCORDANCE IN LUNG FUNCTION IN PATIENTS 
WITH AATD 
6.1 Introduction 
Alpha-1-antitrypsin deficiency (AATD) is associated with the development of early-
onset emphysema especially in patients who smoke. Airflow obstruction and 
impairment of gas transfer are often seen together but this is not universal and even 
patients with severe airflow obstruction and prominent emphysema may have normal 
diffusion capacity as measured by gas transfer, indicating ‘discordant’ lung function 
(Guest et al, 1992; Wilson et al, 2000). These published reports relate to limited 
numbers of patients and so the true incidence of this phenotype is unknown. It is also 
unclear whether these patients with discordant lung function have different health status 
than those patients with both impaired gas transfer and airflow obstruction, so called 
‘concordant’ lung function.  The environmental and/or genetic factors that contribute to 
these alternate phenotypes remain unclear. Thus this study aimed to assess the 
frequency of physiological discordance in severe AATD and to investigate any factors 
which might be associated with the development of discordant disease. 
 
6.2 Methods 
Three hundred and nine patients with severe AATD (PiZ phenotype) were studied. All 
the patients included had measured airflow obstruction with a reduced FEV1 (below 80 
% predicted) after dual bronchodilatation. Demographic details including full smoking 
history were collected at a baseline visit. 
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6.2.1 Lung Function Testing 
Lung function tests were performed as described in Section 3.2. Patients performed 
dynamic spirometry after bronchodilatation with nebulised β2–agonist and ipratropium 
bromide. Gas transfer was measured using the single breath carbon monoxide method.  
 
6.2.2 Health Status 
Three hundred and seven patients had health status assessment using established 
questionnaires. The St George’s Respiratory Questionnaire (SGRQ) was used as a 
disease specific tool with a high score indicating worse health status. The generic Short-
Form 36 (SF36) was also used with a low score indicating worse health status. 
 
6.3 Results 
6.3.1 Patient Characteristics 
Fifty six patients (18%) had a KCO measurement of greater than 80 % predicted despite 
a reduced FEV1 and were classified as “discordant” and 253 patients (82%) had 
“concordant” physiology with both reduced KCO and FEV1. Patient characteristics of 
these two groups are shown in Table 12. 
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Table 12 
 
KCO (% predicted)  
>80 <80 
n= 56 253 
 
 
 
p value* 
Age  
(Years) 
51.4 ± 7.5 51.1 ± 9.5 NS# 
Smoking  
(pack years) 
15.8 (1.0-25.0) 19.0 (9.5-28.0) NS 
Body mass index 
(kg/m2) 
26.4 (24.5-28.6) 24.5 (22.1-27.1) p=0.001 
Gender 
Male 
Female 
 
36 
20 
 
167 
86 
 
NS† 
Chronic Bronchitis 
Yes 
No 
 
29 
27 
 
106 
147 
 
NS† 
Index 
Yes 
No 
 
47 
9 
 
228 
25 
 
NS† 
FEV1  
(% Predicted) 
43.9 (32.6-59.8) 39.1 (28.1-53.1) p=0.022 
FEV1/VC (%) 42.3 
(36.1-54.6) 
31.9 
(24.0-40.1) 
P<0.001 
 
Characteristics and FEV1 of discordant and concordant patients. Data is shown as 
mean ± standard deviation or median (interquartile range). NS: not significant; * 
univariate comparison of the two groups; # t test; † Chi squared test; all other 
statistical comparison used Mann Whitney U test. 
 
 
There was no difference in the age or pack years smoked between the two groups 
although there was a higher proportion of never smokers in the discordant group 
(p=0.006). Patients with discordant physiology had a higher body mass index (BMI) 
(26.4; IQR 24.5-28.6 vs 24.5; IQR 22.1-27.1: p=0.001) than concordant patients. The 
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frequency of chronic bronchitis, index status (identified through lung disease rather than 
family screening) and gender were not different between the two groups. 
6.3.2 Lung Function Data 
The relationship between FEV1 and KCO expressed as percent predicted is illustrated in 
Figure 17. 
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The scatter plot shows the FEV1 and KCO of the study group expressed as percent 
predicted. Subjects with discordant physiology (airflow obstruction but preserved 
gas transfer) are shown by closed circles and those with concordant physiology 
(airflow obstruction and impaired gas transfer) by closed circles. A significant 
correlation is seen between the two variables with a correlation coefficient (r) of 
0.29. 
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Patients with discordant physiology had a higher FEV1 % predicted (43.9; IQR 32.6-
59.8 vs 39.1; IQR 28.1-53.1: p=0.022) than concordant patients.  
6.3.3 Health Status Data 
The health status data is summarised in Table 13. 
 
Table 13 
 KCO (% predicted) 
 >80 <80 
 
n 56 253 p value* 
SGRQ    
Total 55.1 (36.9-68.5) 55.0 (44.5-67.1) NS 
Symptoms 77.9 (49.0-85.8) 68.4 (54.0-79.5) NS 
Activity 67.0 (47.9-82.8) 73.7 (56.9-92.5) NS 
Impact 40.8 (25.0-56.2) 41.8 (28.9-54.0) NS 
SF-36    
Physical 34.5 (26.7-42.3) 34.2 (28.0-41.1) NS 
Mental 55.4 (48.7-58.2) 53.2 (44.3-59.1) NS 
 
Health Status scores of discordant and concordant groups with statistical 
comparison. Values given as median (IQR). NS: not significant.* Mann Whitney U 
test. 
 
No significant difference in health status was seen for either of the questionnaires used 
or their domains between the discordant and concordant groups. 
6.3.4 Predictors of Discordant Disease 
Binary logistic regression showed that the only independent predictors for discordant 
disease were never smoking and higher BMI.  
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6.4 Discussion 
This study confirms that almost many patients with severe alpha-1-antitrypsin 
deficiency have no impairment of gas transfer despite having evidence of airflow 
obstruction. These significant numbers of discordant patients are more likely to be never 
smokers and have a higher body mass index than patients with concordant physiological 
impairment. Despite these features, discordant patients had the same degree of 
impairment of health status as patients with both airflow obstruction and impaired gas 
transfer in this condition.  
Routine measurement of gas transfer often includes a correction for the haemoglobin 
level particularly if it is markedly reduced or elevated. Other factors are known to 
influence the result including height gender and ethnicity but these are often not 
accounted for. The patient’s weight and body mass index may also affect the result. 
One recent study (Saydain et al, 2004) found that patients with a high TLCO had a 
higher body mass index than control subjects of comparable age and height. 
Furthermore, this positive correlation between body mass index persisted when the 
values were corrected for measured alveolar volume. Although the Saydain study was 
investigating subjects with increased diffusion capacity, the relationship between gas 
transfer and BMI supports the results seen in this current study. Greater body weight 
may be associated with a higher blood volume and cardiac output which in turn would 
increase capillary blood volume and increase gas transfer during testing.  However we 
have taken the value of 80% predicted as the cut off for KCO in this study. It is therefore 
possible that the patients in the current study with “preserved KCO” may actually have a 
reduced value compared to their own “supranormal” baseline value. This stresses the 
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importance of viewing isolated one-off measurements in context, as a single value may 
not reflect the severity of gas exchange impairment in one individual. 
The discordant patients in the current study were more likely to be never smokers and 
so this may have led to less severe parenchymal disease. Indeed these patients also had 
significantly less airflow obstruction. The lower body mass index seen in the 
concordant group may be a reflection of more severe underlying disease. Despite this 
no significant difference in health status was seen between the two groups. 
Another possibility is that these two groups of patients may have different phenotypic 
expression of parenchymal disease. In usual COPD the emphysema described 
classically affects the upper zones of the lungs (Thurlbeck, 1963).  Klein et al have 
described COPD patients with impaired gas transfer but relatively preserved airflow 
(Klein et al, 1992), which is the opposite to the pattern described here. This may 
suggest that the pattern and distribution of emphysema may influence impairment seen 
in physiological testing. Parr et al performed quantitative CT scanning in a group of 102 
patients with severe AATD and emphysema and found that 37% of subjects had greater 
involvement in the upper regions (Parr et al, 2004). This is in contrast to the basal 
distribution of emphysema in AATD reported prior to the advent of CT (Gishen et al, 
1982; Mazodier et al, 1971). In addition, Parr et al found that subjects with basal-
distributed emphysema showed greater impairment of FEV1 but less impairment of gas 
exchange than patients with apical- distributed disease despite being matched for total 
volume of emphysema and for age. These differences may be explained by the 
differences in ventilation and perfusion ratio that are seen in the lungs even in health. 
The ventilation/perfusion ratio is more than four times greater in the apices compared to 
the lung bases (West, 1992). It may be that patients with basal emphysema are able to 
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maintain effective gas exchange due to increased perfusion of relatively normal lung in 
the upper zones. However patients with apical disease are unlikely to be able to affect a 
further increase in the already well perfused bases.  
This study has used an arbitrary level of abnormality as 80% predicted. However this 
level does not define the lower limit of normal and some patients with values below this 
level will have normal lung function (Pellegrino et al, 2005). The value of 80% was 
chosen as an arbitrary cut off in the absence of firm guidance on the optimum method 
of expressing the severity of lung function. This cut off point may artificially distort the 
presented data as many more patients than listed will have normal gas transfer. Thus the 
proportion of patients with “discordant” disease is likely to be higher than the numbers 
presented here. 
It is unclear whether the discordant and concordant groups of patients in this study are 
at different points in the natural history and expression of AATD or if they represent 
discrete phenotypic subsets. One study on selective CT quantification showed that 
upper zone analysis was related to all-cause and respiratory mortality (Dawkins et al, 
2003). This may relate to more severe disease progressing from the bases to the apices. 
However it may also represent differences in gas exchange related to emphysema 
distribution. Why this has no influence on health status and how this affects disease 
progression needs further study. 
Further investigation including genetic characterisation, as well as longer term follow 
up, of these heterogeneous subsets of AATD patients will improve our understanding of 
the natural history of this condition. In particular modifier genes may influence both 
emphysema distribution and progression and this should be the basis for future studies. 
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7 GENERAL DISCUSSION 
The current body of work investigates patients selected from the UK registry of alpha-1-
antitrypsin deficiency in Birmingham. One limitation of such studies which use patient 
registries and cohorts is the ascertainment bias of the subjects studied. In the UK 
registry of AATD, 76% of PiZ patients have been identified following investigation of 
respiratory symptoms or disease and 19% through family screening. This is similar to 
the proportions reported in the National Heart Lung and Blood Institute (NHLBI) 
registry (McElvaney et al, 1997). In the current registry, only 3% of patients have been 
identified as a result of liver disease, although it is likely that greater numbers of such 
patients are identified and treated elsewhere in the UK. 
These groups of patients are not fully representative of the whole population of people 
with this deficiency, as recruitment through chest physicians means that symptomatic 
patients are more likely to be enrolled and studied. Population screening is not widely 
performed although one large cohort study is ongoing in Sweden with subjects 
identified through screening at birth (Piitulainen et al, 2002). However the subjects in 
this Swedish study are still less than thirty years of age and so much of the data on the 
natural history of the condition through adult life remains to be collected and studied. 
 
Many people with AATD within the UK population will not have symptoms nor will 
have significant lung function impairment and currently these people are often only 
detected through family screening (Silverman et al, 1989). Furthermore even 
symptomatic individuals will only be identified if the screening test is done and this is 
influenced by local and national practice. Many patients experience a delay of up to 10 
years between the onset of symptoms and diagnosis (Stoller et al, 1994). Thus any 
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descriptive data obtained through registry studies on the natural history of the condition 
cannot be translated to the whole PiZ population, many of whom are not recognised as 
having AATD. However this does not mean that such studies are less useful. Indeed it is 
unlikely that testing for AATD will be introduced into the whole population until a 
definitive treatment is established and so the current targeted methods of identification 
of these individuals will remain. A single centre registry has many advantages for study 
of these patients ensuring consistent measurements, investigation and treatment. It is 
likely that in the future such specialist centres for the investigation and treatment of 
AATD will be disseminated throughout the UK. 
Another type of selection bias that may affect studies involving patient registries is the 
survivor effect, as patients who remain in the study population may retain a certain 
degree of health in order to continue their attendance. This is particularly the case if 
patients have to travel a great distance to the specialist centre. 
 
Alpha-1-antitrypsin replacement is currently not licensed for treatment in the UK. 
However, intravenous replacement is a recognised treatment for deficient patients in 
other countries including the USA, Canada, Germany, Spain, Italy and Sweden. 
Currently there is no clear evidence for the effectiveness of this treatment, as there have 
been no conclusive controlled studies to demonstrate an influence on lung disease. 
Studies have adequately demonstrated that weekly or monthly infusions of AAT are 
safe and can increase plasma and lung fluid levels of AAT (Hubbard et al, 1988; 
Wewers et al, 1987). However it is less clear whether this treatment holds any clinical 
benefit as, to date, any trials have been underpowered or not adequately controlled. 
Clinical trials of any new treatments will need to use defined outcome measures to 
 114
assess an objective response. The effects of the treatment on the frequency and severity 
of exacerbations will be important. Furthermore the quality of life of the patients should 
be investigated alongside symptoms to assess the clinical impact of the treatment. These 
measures could be used together with pulmonary function testing and emphysema 
quantification by CT scan. In order to use these measures as outcomes for trials, we 
must have clear data on the reproducibility and progression of these parameters in the 
natural history of the disease.  
The current standard method for monitoring disease progression in COPD and for 
monitoring the effect of interventions is to measure pulmonary function, in particular 
FEV1. Spirometry has the advantage of a wide evidence base and is readily available, 
inexpensive and relatively simple to perform under supervision of a trained technician. 
However this measurement can be variable and the accuracy of the value obtained is 
dependent on many factors. Furthermore pulmonary function measurements do not 
directly translate into clinically important values for patients and so other outcome 
measures, such as exacerbations and health status, should be included in any 
interventional trials. 
In order for these measurements to be included into trial outcomes accurate information 
is required on the nature and effect of exacerbations in this condition and the effect on 
the health status of patients. Hence the first aims of the current study were to investigate 
these features in a large cohort of AATD patients. The frequency, duration, timing and 
nature of exacerbations were studied as well as host factors that may be associated with 
them. Furthermore the impact of exacerbations on health related quality of life as 
measured by questionnaire was also measured. 
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The results showed that exacerbations occur frequently in patients with AATD and the 
number of exacerbations for the whole group was similar to that seen in non AATD 
COPD in general (Seemungal et al, 1998). Nearly one third of exacerbations occurred in 
December and January and the presence and frequency of exacerbations was generally 
consistent year on year. The median length of symptoms in these patients is 14 days 
which is greater than the 7 days seen in usual COPD (Seemungal et al, 2000a) although 
the current study used different methods for data collection. Patients with chronic 
bronchitis showed an increased frequency of exacerbations, confirming previous 
findings (Dowson et al, 2002). 
Exacerbations were shown to have an influence on health status scores which supports 
data obtained by other groups (Doll et al, 2002; Seemungal et al, 1998). Furthermore 
this association was shown not to be due to a difference in lung function alone as 
exacerbations were found to have an additional independent effect on health status 
scores using regression analysis. Increasing age, chronic bronchitis, and increase in pack 
year smoking history as well as reduced FEV1 were all shown to have independent 
effects on health status scores irrespective of exacerbations. 
Despite major changes in lung function over the 3 year study period health status did 
not decline. It is possible that this is due to benefits of being seen in a specialist clinic 
for alpha-1-antitrypsin deficiency. 
 
A further aim of the current work was to investigate the changes in lung function and 
health status in patients with severe alpha-1-antitrypsin deficiency over time. Lung 
physiology measurements were shown to deteriorate in these patients over time. 
However the decline in spirometric values was not related to the frequency of 
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exacerbations in the whole group or in subgroups according to airflow obstruction. This 
is contrary to the findings in patients with  usual COPD (Donaldson et al, 2002). The 
current study did however show that the number of exacerbations was associated with 
decline in gas transfer.  
These study data provide a firm basis upon which to design, power and implement 
clinical trials in alpha-1-antitrypsin deficiency using exacerbations and health status as 
outcome measures. 
  
Cigarette smoking is the most important environmental risk factor for COPD and yet 
only around 15% of smokers develop clinically significant disease (Fletcher et al, 
1977). Genetic factors are also important in the development of the disease as identified 
in alpha-1-antitrypsin deficiency. Other genetic factors are likely to also influence 
disease and this is supported by the observation of higher incidence of airflow 
obstruction in first-degree relatives of patients with usual COPD (Kueppers et al, 1977). 
Other studies of families with early-onset COPD show lower FEV1 values in relatives of 
probands despite similar age and smoking history (Silverman et al, 1998). These same 
or other host factors may also influence the expression of the disease within the 
individual and the progression of the disease over time. The Silverman study showed 
that the increased risk for airflow obstruction was limited to current or ex-smokers, with 
no risk of reduced FEV1 in lifelong non-smokers. This supports the hypothesis of a 
genotype-environment interaction which is defined as a non-additive contribution of 
gene and environment towards the clinical phenotype. Thus the two influences confer a 
different level of risk than that expected by simply adding each effect together.  
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These gene-environment interactions may also be important in the expression of disease 
in alpha-1-antitrypsin deficiency. There has been little evidence to support genetic 
modifiers in families with more than one homozygote member although studies of 
heterozygote relatives using pulmonary function and respiratory questionnaire do 
suggest familial aggregation (Silverman et al, 1989; Silverman et al, 1990b). 
Furthermore parents of diseased PiZ individuals were more likely to report a history of 
emphysema than parents of unaffected PiZ individuals in the same study, which is 
consistent with COPD aggregation in families.  
Sibling pairs with this deficiency have not been widely studied although case reports of 
individual sibships have suggested that the lung disease of PiZ siblings may be 
discordant (Apprill et al, 1990; Stableforth, 1978). This led to a further aim of the 
current work to identify sibling pairs of patients with severe deficiency and to compare 
cross-sectional lung function data and health status measurements between index and 
non-index siblings. 
The current study shows that there is no correlation in FEV1 values between the index 
siblings and non-index siblings, even when values were adjusted for differences in 
personal smoking history. Furthermore, this discordance was also seen in the pairs of 
non-index siblings identified by family screening who would not be affected by 
ascertainment bias, although the study numbers were small. Taken together, these 
results suggest that there is another factor or factors that vary between these sibling 
pairs that influences the susceptibility of lung disease. This could be a factor that 
increases the risk of one sibling or indeed a factor that has a protective effect on the less 
severely affected sibling. It is more likely that there are a number of factors at play. 
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In contrast to the spirometry results, this study has shown that gas transfer values do 
correlate between the sibling pairs, indicating physiological concordance for this 
measure. This may suggest that the different phenotypes of parenchymal disease and 
airway disease may be affected by alternate subsets of genes which influence the 
underlying pathological changes. Alternatively, the parenchymal disease may be more 
closely related to the alpha-1-antitrypsin deficiency itself and less affected by modifier 
genes. These hypotheses provide a sound background for further genetic investigation 
of sibling pairs with AATD in the future. 
 
The final part of the current work set out to investigate the presence of physiological 
discordance in a larger set of individuals with AATD. It was found that significant 
numbers, almost one fifth of patients, with severe alpha-1-antitrypsin deficiency have 
no impairment of gas transfer despite having evidence of airflow obstruction. These 
discordant patients are more likely to be never smokers and also have a higher body 
mass index than patients with concordant physiological impairment. However despite 
preservation of gas transfer values, discordant patients show the same degree of 
impairment of health status as patients with airflow obstruction and impaired gas 
transfer in this condition.  
  
COPD is a complex disease and a variety of phenotypes are expressed even within a 
well-defined population such as the current study subjects. Thus it is likely that there are 
a number of genes and genotype-environment interactions that have additive, 
synergistic or even protective effects. These complex interactions should be accounted 
for when interpreting the results of genetic studies.  
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Some genetic loci associated with  spirometric measures and lung function change have 
already been identified in patients with usual COPD (Gottlieb et al, 2001; Joost et al, 
2002; Wilk et al, 2003). These or other genetic modifiers may also influence the risk of 
COPD development in AATD. Genome wide linkage and association studies in families 
of PiZ individuals, similar to those performed in usual COPD, may identify other 
putative genes in the future and the “discordant” sibling pairs identified in the current 
work would be an ideal group for investigation with this concept in mind. Careful 
selection of a study population containing well characterised families with disparate 
lung function would improve the potential for such work to identify other genetic 
factors that are associated with phenotype. Furthermore study of subsets of PiZ 
individuals with differing patterns of lung function impairment may also yield results. 
These studies may lead to identification of putative genes that modify and influence the 
development and progression of lung disease in AATD subjects. Any positive findings 
may then be studied further in COPD patients without severe AAT deficiency. This may 
lead to improved understanding of the pathogenesis of lung disease in patients with and 
without alpha-1-antitrypsin deficiency. 
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APPENDIX 1 
CONSENT FORM FOR PARTICIPATION IN RESEARCH 
 
Assessment for Alpha1 Antitrypsin Deficiency 
 
What is the study about? 
 
You or a member of your family has been identified as having alpha1 antitrypsin 
deficiency.  This is an inherited condition that is believed to increase the risk of 
development of lung health problems.  However very little detailed information has 
been collected on the way this deficiency affects patients and some studies have 
suggested that lung disease may run in families even without the deficiency.  It is likely 
however that the deficiency highlights the tendency to develop these diseases and when 
present will make them worse. 
 
We wish to learn as much as possible about the deficiency and its relationship to lung 
disease and for this reason invite you to participate in our alpha1 antitrypsin deficiency 
assessment programme. 
 
What will I have to do? 
 
In broad terms you will undergo all the routine questioning, examination and tests that 
we normally undertake when assessing somebody who presents with lung disease.  
However we hope to do this more carefully and in more detail than is routinely carried 
out by your own doctor or specialist. 
 
We will ask many questions about your past and present symptoms, health and 
wellbeing.  In addition you will be examined thoroughly to determine the presence of 
signs related to lung disease.  After this screening programme you will be asked to 
perform some lung function testing which assesses how your lungs work and their 
ability to take oxygen in and out of your body.  We may also perform a specialised CT 
scan of your lungs (if you have not had one) which is a very sensitive technique of 
detecting damage that has occurred.  Finally we will ask you to provide one blood 
sample and if you have a cough productive of sputum we will arrange for you to collect 
this over several hours on one day before coming to see us. 
 
Once all these tests have been performed we will be able to determine whether you 
have lung disease related to alpha1 antitrypsin deficiency.  This will be explained to you 
and any modifications in your treatment that are indicated will be communicated to 
both yourself and your own doctor. 
 
It is our general clinical routine to follow patients with established lung disease on a 
long-term basis.  Patients are usually seen once every 4-6 months to assess their 
wellbeing and follow any progress in the condition.  If you have alpha1 antitrypsin 
deficiency we would wish to see you once a year to assess your symptoms, clinical 
signs and repeat the extensive lung function tests and the CT scan to confirm the extent 
or any progression of your disease will be carried out every 2 years.  After the first year 
the lung function may be repeated less frequently (2 or 3 yearly) depending on whether 
these are changing or are stable. 
 
NOTE The CT scan exposes you to a small degree of radiation – about the equivalent 
of 6 months background radiation in the UK.  Although this dose is safe (it is the same 
as a single x-ray of the abdomen), it is important that you inform us if you are likely to 
be pregnant as we will not carry out the test in these circumstances.   
 
What are the benefits? 
 
The major purpose of the study is to find out as much as possible about the lung disease 
associated with alpha1 antitrypsin deficiency.  This will provide the background 
information that enables us to design studies to assess the role of alpha1 antitrypsin 
replacement therapy in both the short and long term.  The investigations that we 
undertake will allow us to advise upon the degree of lung disease that you have and 
simple measures that you can undertake with your current treatment in order to try and 
stabilize the lung disease.  In addition the breathing tests that we will perform will help 
us to optimize your current treatment in order to improve your breathlessness where 
possible. 
 
What are the risks? 
 
All the investigations that are taking place are entirely routine, used in the assessment 
of patients with lung disease.  As such they are repeated on many occasions in the same 
patient without any adverse effects.  The only minor problem that is likely to occur is a 
slight degree of bruising in some patients when they have their blood taken. 
 
What are the alternatives? 
 
There are currently no alternatives to finding the information that is required other than 
the assessment programme outlined above. 
 
What happens if I do not wish to take part? 
 
If you do not wish to participate in the assessment programme or the short term follow 
up programme this will be fully understood.  Your own general practitioner, or the 
consultant chest physician who normally looks after you, will be informed of the 
diagnosis and provided with advice on how to assess and manage your follow up along 
the lines outlined above.  If for any reason they or you require further advice from us in 
the future we will be only too pleased to see you.  It is important to emphasize that your 
overall management by your doctor will not be affected by your decision. 
 
What happens to the information? 
 
The important information that we collect over the next year or two will be written up 
as a report and submitted to medical journals so that other doctors may read about the 
problem.  The research information obtained from the samples that we have collected 
will be the basis for future studies on the role of alpha1 antitrypsin replacement therapy 
which we hope to start within the next 12-18 months.  Neither your name or any details 
relating to you personally will be released to any other person outside the research 
programme. 
 
Who is taking part? 
 
All subjects that we identify with alpha1 antitrypsin deficiency and in some cases 
members of their family will be asked to take part.  At present we know of over 800 
such patients as yourself and it is likely that there are several thousand similar people in 
the West Midlands alone.  It is hoped over the next year or two to identify and assess all 
people with the deficiency in the Midlands. 
 
What if something goes wrong? 
 
The question largely relates to clinical trials and at present that is not part of the 
assessment programme.  If you develop new symptoms for any reason during the 
assessment day this will be in the presence of a doctor who will take any steps that are 
necessary to help you.  In between visits to the assessment centre your own doctor will 
be largely responsible for your care but (depending on where you live) we may 
collaborate with your doctor and help by seeing you if you become unwell. 
 
What happens at the end of a study? 
 
At the end of the study we will have learnt a lot about alpha1 antitrypsin deficiency.  If 
you remain part of the programme for assessment we will be having regular meetings 
for all patients to attend to discuss how the assessment programme is going and how 
our understanding is developing.  If for any reason you are unable to attend we will be 
keeping in touch with you by letter and newsletter to inform you of the progress of the 
programme. 
 
What if I have more questions or do not understand something? 
 
The doctors, co-ordinator and nurse involved in the alpha1 antitrypsin assessment 
programme will happily answer your questions on any occasion when you visit.  If 
questions arise between visits you will be able to contact the centre and either speak to 
somebody at that time or arrange to do so if for any reason if it is inconvenient. 
 
What happens now if I decide to take part? 
 
If you decide to take part in the programme now we will arrange an appointment in the 
not too distant future for you to come to the assessment centre for the investigations 
outlined above.  This will be arranged to suit everybody’s convenience and all the 
assessment will be completed where possible on a single visit. 
 
What happens if I change my mind during the study? 
 
If you change your mind during the study, it is important that you notify the assessment 
centre.  This will enable any investigations that have been organized or visits to be 
cancelled.  Your decision will be passed on to both your own doctor and where 
appropriate your own specialist in order that they can arrange for appropriate 
appointments to monitor your progress.  Providing you are agreeable we would like to 
contact your own doctor or specialist from time to time in order to find out how you are 
progressing.  However if in the future you once again decide to join the programme, we 
would be only too pleased to see you. 
 [Contact details]
  
 
CONSENT FORM FOR PARTICIPATION IN RESEARCH 
 
Assessment for Alpha1 Antitrypsin Deficiency 
 
 
 
  Please Initial 
    
  Yes No 
I………………………………………………………………
……… voluntarily agree to participate in the alpha1 
antitrypsin deficiency assessment programme. 
   
  Yes No 
I have been given a full explanation of the programme and 
read the patient information sheet and have had all my 
questions answered and agreed to cooperate where possible 
with this programme. 
   
  Yes No 
I understand that that if I suffer from any unexpected 
problems that it may be important to contact both my own 
doctor and the staff at the alpha-1-antitrypsin resource centre. 
   
  Yes No 
I understand fully that I am free to withdraw from the 
programme at any time without giving a reason and that this 
will not adversely affect my future management. 
   
    
 
 
Signed (Patient)……………..…………………………………………..…  
 
Date ……………………………………………………………………….. 
 
 
 
 
Signed (Witness)…………………………………………………………. 
 
Date………………………………………………………………………...
 
 
 
 
APPENDIX 2 
THE ST. GEORGE'S HOSPITAL RESPIRATORY QUESTIONNAIRE 
 
 
This questionnaire is designed to help us learn much more about how your breathing 
is troubling you and how it affects your life. We are using it to find out which 
aspects of your illness cause you most problem, rather than what the doctors and 
nurses think your problems are.  
 
Please read the instructions carefully and ask if you do not understand any thing. Do 
not spend too long deciding about your answers. 
 
 
 
 
 
 
 
 
_________________________________________________________ 
 
Name: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  Date: _ _ _ _ _ _ _ _ _ 
    
 
I.D. no.  _ _  _ _ _  _ _  _ 
 
 
Age:   _ _ _ _ _ _ _ _ _   Sex: 
Male/Female 
 
 
 
 
 
 
Before completing the rest of the questionnaire, please tick in the circle to show how 
you describe your current health 
 
 
 
 Very Good O 
 
 Good O 
 
 Fair O 
 
 Poor O 
 
                                                Very Poor        O 
 
PART 1 
 
QUESTIONS ABOUT HOW MUCH CHEST TROUBLE YOU HAVE HAD OVER THE LAST YEAR. 
PLEASE TICK IN ONE BOX FOR EACH QUESTION. 
 most  several a few  only with not 
 days days days a chest at 
 a week a week a month infections all 
 
1) Over the last year, I have coughed:      
2) Over the last year, I have brought  
up phlegm (sputum):      
3) Over the last year, I have had  
shortness of breath:      
4) Over the last year, I have had attacks  
of wheezing:      
 
5) During the last year, how many severe or very 
unpleasant attacks of chest trouble have you had:   
   more than 3 attacks   
  3 attack   
  2 attacks   
  1 attack   
  no attacks   
6) How long did the worst attack of chest trouble last:   
(Go to Question 7 if you had no severe attacks)  
  a week or more  
  3 or more days  
  1 or 2 days  
  less than a day  
 
7) Over the last year, in an average week, how many good days  
(with little chest trouble) have you had: 
  no good days   
    1 or 2 good days   
  3 or 4 good days   
  nearly every day is good  
  every day is good  
 
8) If you have a wheeze, is it worse in the morning: 
 no  
 yes  
 
PART 2 
SECTION 1: 
HOW WOULD YOU DESCRIBE YOUR CHEST CONDITION? 
(PLEASE TICK IN ONE BOX ONLY) 
  
 the most important problem I have  
 causes me quite a lot a problems  
 causes me a few problems  
 causes no problem  
 
IF YOU HAVE EVER HAD PAID EMPLOYMENT, PLEASE TICK ONE OF THESE: 
 my chest trouble made me stop work altogether  
 my chest trouble interferes with my work or made me change my work  
 my chest trouble does not affect my work  
 
SECTION 2:  
QUESTIONS ABOUT WHAT ACTIVITIES USUALLY MAKE YOU FEEL BREATHLESS THESE 
DAYS. FOR EACH ITEM, PLEASE TICK IN THE BOX FOR EITHER TRUE OR FALSE AS IT 
APPLIES TO YOU 
    
 Sitting or lying still  True   False 
  Getting washed or dressed  True   False 
 Walking around the home  True   False 
 Walking outside on the level  True   False 
 Walking up a flight of stairs  True   False 
 Walking up hills  True   False 
 Playing sports or games  True   False 
 
SECTION 3:  
SOME MORE QUESTIONS ABOUT YOUR COUGH AND BREATHLESSNESS THESE DAYS. 
FOR EACH ITEM, PLEASE TICK IN THE BOX FOR EITHER TRUE OR FALSE AS IT APPLIES TO 
YOU 
 
  My cough hurts  True   False 
 My cough makes me tired  True   False 
 I am breathless when I talk  True   False 
 I am breathless when I bend over  True   False 
 My cough or breathing disturbs my sleep  True   False 
  I get exhausted easily  True   False 
 
SECTION 4:  
QUESTIONS ABOUT OTHER EFFECTS THAT YOUR CHEST TROUBLE MAY HAVE ON YOU 
THESE DAYS. FOR EACH ITEM, PLEASE TICK IN THE BOX FOR EITHER TRUE OR FALSE AS IT 
APPLIES TO YOU 
 
 My cough or breathing is embarrassing in public  True   False 
 My chest trouble is a nuisance to my family,  
  friends or neighbours  True   False 
 I get afraid or panic when I cannot get my breath  True   False 
 I feel that I am not in control of my chest problem  True   False 
 I do not expect my chest to get any better  True   False 
 I have become frail or an invalid because of my chest  True   False 
 Exercise is not safe for me  True   False 
 Everything seems too much of an effort  True   False 
 
SECTION 5:  
QUESTIONS ABOUT YOUR MEDICATION. IF YOU ARE RECEIVING NO MEDICATION GO 
STRAIGHT TO SECTION 6. TO COMPLETE THIS SECTION PLEASE TICK IN THE BOX FOR 
EITHER TRUE OR FALSE AS IT APPLIES TO YOU 
 
 My medication does not help me very much  True   False 
 I get embarrassed using my medication in public   True   False 
 I have unpleasant side effects from my medication  True   False 
 My medication interferes with my life a lot  True   False 
 
 
SECTION 6:  
THESE ARE QUESTIONS ABOUT HOW YOUR ACTIVITIES MIGHT BE AFFECTED BY YOUR 
BREATHING. FOR EACH QUESTION, PLEASE TICK TRUE IF ONE OR MORE OF THE PARTS 
OF THE QUESTION APPLIES TO YOU BECAUSE OF YOUR BREATHING. OTHERWISE TICK 
FALSE.  
 
 I take a long time to get washed or dressed  True   False 
 I cannot take a bath or shower, or I take a long time  True   False 
 I walk slower than other people, or I stop for rests  True   False 
 Jobs such as housework take a long time,  
  or I have to stop for rests  True   False 
 If I walk up one flight of stairs,  
  I have to go slowly or stop  True   False 
 If I hurry or walk fast, I have to stop or slow down  True   False 
  
 My breathing makes it difficult to do things such as 
  walk up hills, carrying things up stairs, light gardening  
 such as weeding, dance, play bowls or play golf  True   False 
 
 My breathing makes it difficult to do things such as  
 carry heavy loads, dig the garden or shovel snow,  
 jog or walk at 5 miles per hour, play tennis or swim  True   False  
 
 My breathing makes it difficult to do things such as  
 very heavy manual work, run, cycle, swim fast 
 or play competitive sports  True   False 
 
SECTION 7:  
WE WOULD LIKE TO KNOW HOW YOUR CHEST TROUBLE USUALLY AFFECTS YOUR DAILY 
LIFE. PLEASE TICK EITHER TRUE OR FALSE (REMEMBER THAT TRUE ONLY APPLIES TO YOU 
IF YOU CANNOT DO SOMETHING BECAUSE OF YOUR BREATHING) 
 
 I cannot play sports or games  True   False 
 I cannot go out for entertainment or recreation  True   False 
 I cannot go out of the house to do the shopping  True   False 
 I cannot do housework  True   False 
 I cannot move far from my bed or chair  True   False 
 
HERE IS A LIST OF OTHER ACTIVITIES THAT YOUR CHEST TROUBLE MAY PREVENT YOU 
DOING. (YOU DO NOT HAVE TO TICK THESE, THEY ARE JUST TO REMIND YOU OF WAYS IN 
WHICH YOUR BREATHLESSNESS MAY AFFECT YOU): 
 
 GOING FOR WALKS OR WALKING THE DOG 
 DOING THINGS AT HOME OR IN THE GARDEN  
 SEXUAL INTERCOURSE 
 GOING OUT TO CHURCH, OR PLACE OF ENTERTAINMENT  
 GOING OUT IN BAD WEATHER OR INTO SMOKY ROOMS 
 VISITING FAMILY OR FRIENDS OR PLAYING WITH CHILDREN 
 
 
 
PLEASE WRITE IN ANY OTHER IMPORTANT ACTIVITIES THAT YOUR CHEST TROUBLE MAY 
STOP YOU DOING:  
_ _ _ _ _ _ _ _ _ _ _  _ _ _  _ _  _ _ _ _ _ _  _ _ _  _ _  _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
_ _ _ _ _ _ _ _ _ _ _  _ _ _  _ _  _ _ _ _ _ _  _ _ _  _ _  _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
_ _ _ _ _ _ _ _ _ _ _  _ _ _  _ _  _ _ _ _ _ _  _ _ _  _ _  _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
 
 
 
NOW, WOULD YOU TICK IN THE BOX (ONE ONLY) WHICH YOU THINK BEST DESCRIBES 
HOW YOUR CHEST AFFECTS YOU: 
 
 It does not stop me doing anything I would like to do  
 It stops me doing one or two things I would like to do  
 It stops me doing most of the things I would like to do  
 It stops me doing everything I would like to do  
 
 
 
Copyright reserved 
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APPENDIX 3 
THE SF-36TM HEALTH SURVEY 
 
INSTRUCTIONS: this survey asks for your views about your health. This information 
will help you keep track of how you feel and how well you are able to do your usual 
activities. If you are unsure about how to answer a question, please give the best answer 
you can.  
 
Question 1 
 
In general, would you say your health is: 
 
 Excellent    
 Very Good   
 Good   
 Fair   
 Poor   
 
Question 2 
 
Compared to ONE YEAR AGO, how would you rate your health in general now? 
 
 Much better than one year ago  
 Somewhat better now than one year ago  
 About the same as one year ago  
 Somewhat worse now than one year ago  
 Much worse now than one year ago  
 
Question 3 
 
The following items are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much? 
 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
a) Vigorous activities such as running, lifting heavy 
objects, participating in strenuous sports? 
   
b) Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf? 
   
c) Lifting or carrying groceries?    
d) Climbing several flights of stairs?    
e) Climbing one flight of stairs?    
f) Bending, kneeling or stooping?    
g) Walking more than a mile?    
h) Walking half a mile?    
i) Walking 100 yards?    
j) Bathing or dressing yourself?    
 
 
Question 4 
 
During the past 4 weeks, have you had any of the following problems with your work 
or other regular activities as a result of your physical health? 
 
 Yes No 
a) Cut down on the amount of time 
you spent on work or other activities? 
  
b) Accomplished less than you would 
like? 
 
 
 
 
c) Were limited in the kind of work or 
other activities? 
 
 
 
 
d) Had difficulty performing the work 
or other activities (for example it took 
extra effort)? 
  
 
 
Question 5 
 
During the past 4 weeks, how much time have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional problems? 
 
 Yes No 
a) Cut down on the amount of time 
you spent on work or other activities? 
  
b) Accomplished less than you would 
like? 
 
 
 
 
c) Didn’t do work or other activities as 
carefully as usual? 
 
 
 
 
 
 
Question 6 
 
During the past 4 weeks, to what extent have your physical health or emotional 
problems interfered with your normal social activities with family, neighbours or 
groups? 
 
 Not at all   
 Slightly   
 Moderately   
 Quite a bit   
 Extremely   
 
 
 
Question 7 
 
How much bodily pain have you had during the past 4 weeks? 
 
 None   
 Very mild   
 Mild   
 Moderate   
 Severe   
 Very severe  
 
 
Question 8 
 
During the past 4 weeks, how much did pain interfere with your normal work 
(including both outside the home and housework)? 
 
 Not at all   
 Slightly   
 Moderately   
 Quite a bit   
 Extremely   
 
Question 9 
 
These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question please give one answer that comes closest to the way 
you have been feeling. How much time during the last 4 weeks: 
 
 All of 
the 
time 
Most 
of the 
time 
A 
good 
bit of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None  
of the 
time 
a) Did you feel full of life? 
 
      
b) Have you been a very 
nervous person? 
 
 
 
 
 
 
 
 
 
 
 
c) Have you felt so down in 
the dumps that nothing 
would cheer you up? 
 
 
 
 
 
 
 
 
 
 
 
d) Have you felt calm and 
peaceful? 
      
e) Did you have a lot of 
energy? 
      
f) Have you felt downhearted 
and low? 
 
 
 
 
 
 
 
 
 
 
 
g) Did you feel worn out?  
 
 
 
 
 
 
 
 
 
 
h) Have you been a happy 
person? 
      
i) Did you feel tired? 
 
      
 
 
Question 10 
 
During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives etc)? 
 
 All of the time   
 Most of the time   
 Some of the time   
 A little of the time   
 None of the time   
 
 
Question 11 
 
How TRUE or FALSE is each of the following statements for you? 
 
 Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
a) I seem to get ill more easily 
than other people 
     
b) I am as healthy as anybody 
I know 
 
 
 
 
 
 
 
 
 
c) I expect my health to get 
worse 
 
 
 
 
 
 
 
 
 
d) My health is excellent 
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